{"status": "ok", "message-type": "work-list", "message-version": "1.0.0", "message": {"facets": {}, "total-results": 5720, "items": [{"indexed": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T03:43:41Z", "timestamp": 1574135021465}, "reference-count": 0, "publisher": "Springer Science and Business Media LLC", "issue": "S2", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2000, 10, 1]], "date-time": "2000-10-01T00:00:00Z", "timestamp": 970358400000}, "delay-in-days": 0, "content-version": "unspecified"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Breast Cancer Res"], "published-print": {"date-parts": [[2000, 10]]}, "DOI": "10.1186/bcr243", "type": "journal-article", "created": {"date-parts": [[2002, 9, 26]], "date-time": "2002-09-26T12:07:27Z", "timestamp": 1033042047000}, "source": "Crossref", "is-referenced-by-count": 0, "title": ["Flexible screening clinics: future options"], "prefix": "10.1186", "volume": "2", "author": [{"given": "SA", "family": "Dyson", "sequence": "first", "affiliation": []}, {"given": "VA", "family": "Milnes", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2000, 10, 1]]}, "container-title": ["Breast Cancer Research"], "language": "en", "link": [{"URL": "http://link.springer.com/content/pdf/10.1186/bcr243.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/article/10.1186/bcr243/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/content/pdf/10.1186/bcr243.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 1, 18]], "date-time": "2017-01-18T10:24:37Z", "timestamp": 1484735077000}, "score": 24.859964, "issued": {"date-parts": [[2000, 10]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2000, 10]]}, "issue": "S2"}, "alternative-id": ["242"], "URL": "http://dx.doi.org/10.1186/bcr243", "ISSN": ["1465-542X"], "issn-type": [{"value": "1465-542X", "type": "electronic"}], "article-number": "A54"}, {"indexed": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T16:57:24Z", "timestamp": 1574873844268}, "reference-count": 0, "publisher": "American Association for Cancer Research (AACR)", "issue": "9", "content-domain": {"domain": ["aacrjournals.org"], "crossmark-restriction": true}, "short-container-title": ["Cancer Epidemiol Biomarkers Prev"], "published-print": {"date-parts": [[2018, 9]]}, "DOI": "10.1158/1055-9965.epi-18-0264", "type": "journal-article", "created": {"date-parts": [[2018, 9, 4]], "date-time": "2018-09-04T07:25:47Z", "timestamp": 1536045947000}, "page": "985-994", "update-policy": "http://dx.doi.org/10.1158/aacr-crossmark-policy", "source": "Crossref", "is-referenced-by-count": 3, "title": ["Cancer Progress and Priorities: Uterine Cancer"], "prefix": "10.1158", "volume": "27", "author": [{"given": "Ashley S.", "family": "Felix", "sequence": "first", "affiliation": []}, {"given": "Louise A.", "family": "Brinton", "sequence": "additional", "affiliation": []}], "member": "1086", "published-online": {"date-parts": [[2018, 9, 4]]}, "container-title": ["Cancer Epidemiology Biomarkers & Prevention"], "language": "en", "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/1055-9965.EPI-18-0264", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2018, 9, 4]], "date-time": "2018-09-04T07:26:05Z", "timestamp": 1536045965000}, "score": 23.548916, "issued": {"date-parts": [[2018, 9]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2018, 9, 4]]}, "published-print": {"date-parts": [[2018, 9]]}, "issue": "9"}, "alternative-id": ["10.1158/1055-9965.EPI-18-0264"], "URL": "http://dx.doi.org/10.1158/1055-9965.epi-18-0264", "ISSN": ["1055-9965", "1538-7755"], "issn-type": [{"value": "1055-9965", "type": "print"}, {"value": "1538-7755", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T14:38:36Z", "timestamp": 1574174316401}, "reference-count": 85, "publisher": "Springer Science and Business Media LLC", "issue": "1", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2005, 12, 16]], "date-time": "2005-12-16T00:00:00Z", "timestamp": 1134691200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Cancer Immunol Immunother"], "published-print": {"date-parts": [[2006, 11, 6]]}, "DOI": "10.1007/s00262-005-0110-x", "type": "journal-article", "created": {"date-parts": [[2005, 12, 16]], "date-time": "2005-12-16T11:01:49Z", "timestamp": 1134730909000}, "page": "81-87", "source": "Crossref", "is-referenced-by-count": 47, "title": ["Tumor escape mechanisms in prostate cancer"], "prefix": "10.1007", "volume": "56", "author": [{"given": "Ashley M.", "family": "Miller", "sequence": "first", "affiliation": []}, {"given": "Pavel", "family": "Pisa", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2005, 12, 16]]}, "reference": [{"key": "110_CR1", "doi-asserted-by": "crossref", "first-page": "1075", "DOI": "10.1016/S0959-8049(96)00492-3", "volume": "33", "author": "RJ Black", "year": "1997", "unstructured": "Black RJ, Bray F, Ferlay J, Parkin DM (1997) Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer 33:1075\u20131107", "journal-title": "Eur J Cancer"}, {"key": "110_CR2", "doi-asserted-by": "crossref", "first-page": "10", "DOI": "10.3322/canjclin.55.1.10", "volume": "55", "author": "A Jemal", "year": "2005", "unstructured": "Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ (2005) Cancer Statistics, 2005. CA Cancer J Clin 55:10\u201330", "journal-title": "CA Cancer J Clin"}, {"key": "110_CR3", "doi-asserted-by": "crossref", "first-page": "193", "DOI": "10.1007/s10147-003-0332-x", "volume": "8", "author": "M Harada", "year": "2003", "unstructured": "Harada M, Noguchi M, Itoh K (2003) Target molecules in specific immunotherapy against prostate cancer. Int J Clin Oncol 8:193\u2013199", "journal-title": "Int J Clin Oncol"}, {"key": "110_CR4", "doi-asserted-by": "crossref", "first-page": "80", "DOI": "10.1002/pros.10276", "volume": "57", "author": "M Noguchi", "year": "2003", "unstructured": "Noguchi M, Kobayashi K, Suetsugu N, Tomiyasu K, Suekane S, Yamada A, Itoh K, Noda S (2003) Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination. Prostate 57:80\u201392", "journal-title": "Prostate"}, {"key": "110_CR5", "doi-asserted-by": "crossref", "first-page": "688", "DOI": "10.1038/sj.bjc.6602019", "volume": "91", "author": "M Pavlenko", "year": "2004", "unstructured": "Pavlenko M, Roos AK, Lundqvist A, Palmborg A, Miller AM, Ozenci V, Bergman B, Egevad L, Hellstrom M, Kiessling R et al (2004) A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer 91:688\u2013694", "journal-title": "Br J Cancer"}, {"key": "110_CR6", "first-page": "1632", "volume": "6", "author": "JP Eder", "year": "2000", "unstructured": "Eder JP, Kantoff PW, Roper K, Xu GX, Bubley GJ, Boyden J, Gritz L, Mazzara G, Oh WK, Arlen P et al (2000) A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res 6:1632\u20131638", "journal-title": "Clin Cancer Res"}, {"key": "110_CR7", "doi-asserted-by": "crossref", "first-page": "412", "DOI": "10.1111/j.1464-410X.2004.04922.x", "volume": "94", "author": "HS Pandha", "year": "2004", "unstructured": "Pandha HS, John RJ, Hutchinson J, James N, Whelan M, Corbishley C, Dalgleish AG (2004) Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study. BJU Int 94:412\u2013418", "journal-title": "BJU Int"}, {"key": "110_CR8", "first-page": "5160", "volume": "59", "author": "JW Simons", "year": "1999", "unstructured": "Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Lim M, Weber CE, Baccala AA, Goemann MA, Clift SM, et al (1999) Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 59:5160\u20135168", "journal-title": "Cancer Res"}, {"key": "110_CR9", "doi-asserted-by": "crossref", "first-page": "44", "DOI": "10.1038/ncpuro0079", "volume": "2", "author": "J Vieweg", "year": "2005", "unstructured": "Vieweg J, Dannull J (2005) Technology insight: vaccine therapy for prostate cancer. Nature Clinical Practice Urology 2:44\u201351", "journal-title": "Nature Clinical Practice Urology"}, {"key": "110_CR10", "doi-asserted-by": "crossref", "first-page": "353", "DOI": "10.1007/s002620050586", "volume": "48", "author": "R Kiessling", "year": "1999", "unstructured": "Kiessling R, Wasserman K, Horiguchi S, Kono K, Sjoberg J, Pisa P, Petersson M (1999) Tumor-induced immune dysfunction. Cancer Immunol Immunother 48:353\u2013362", "journal-title": "Cancer Immunol Immunother"}, {"key": "110_CR11", "doi-asserted-by": "crossref", "first-page": "262", "DOI": "10.1007/s00262-003-0469-5", "volume": "53", "author": "G Pawelec", "year": "2004", "unstructured": "Pawelec G (2004) Tumour escape: antitumour effectors too much of a good thing? Cancer Immunol Immunother 53:262\u2013274", "journal-title": "Cancer Immunol Immunother"}, {"key": "110_CR12", "doi-asserted-by": "crossref", "first-page": "844", "DOI": "10.1007/s00262-004-0540-x", "volume": "53", "author": "M Ahmad", "year": "2004", "unstructured": "Ahmad M, Rees RC, Ali SA (2004) Escape from immunotherapy: possible mechanisms that influence tumor regression/progression. Cancer Immunol Immunother 53:844\u2013854", "journal-title": "Cancer Immunol Immunother"}, {"key": "110_CR13", "unstructured": "Humphrey P (2003) Prostate pathology: American society clinical Pathology"}, {"key": "110_CR14", "doi-asserted-by": "crossref", "first-page": "232", "DOI": "10.1016/S0022-5347(17)60173-3", "volume": "110", "author": "MR Megalli", "year": "1973", "unstructured": "Megalli MR, Gursel EO, Veenema RJ (1973) Ascites as an unusual presentation of carcinoma of the prostate. J Urol 110:232\u2013234", "journal-title": "J Urol"}, {"key": "110_CR15", "doi-asserted-by": "crossref", "first-page": "20", "DOI": "10.1002/pros.20229", "volume": "65", "author": "V Ozenci", "year": "2005", "unstructured": "Ozenci V, Miller AM, Palmborg A, Egevad L, Jaremko GA, Kalkner KM, Pisa P (2005) Presence and specificity of tumor associated lymphocytes from ascites fluid in prostate cancer. Prostate 65:20\u201326", "journal-title": "Prostate"}, {"key": "110_CR16", "doi-asserted-by": "crossref", "first-page": "1797", "DOI": "10.1016/0959-8049(94)E0159-2", "volume": "30A", "author": "S Vesalainen", "year": "1994", "unstructured": "Vesalainen S, Lipponen P, Talja M, Syrjanen K (1994) Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur J Cancer 30A:1797\u20131803", "journal-title": "Eur J Cancer"}, {"key": "110_CR17", "doi-asserted-by": "crossref", "first-page": "467", "DOI": "10.1016/S0090-4295(99)00152-1", "volume": "54", "author": "J Irani", "year": "1999", "unstructured": "Irani J, Goujon JM, Ragni E, Peyrat L, Hubert J, Saint F, Mottet N (1999) High-grade inflammation in prostate cancer as a prognostic factor for biochemical recurrence after radical prostatectomy. Pathologist Multi Center Study Group. Urology 54:467\u2013472", "journal-title": "Urology"}, {"key": "110_CR18", "doi-asserted-by": "crossref", "first-page": "541", "DOI": "10.1038/sj.bjc.6601943", "volume": "91", "author": "PA McArdle", "year": "2004", "unstructured": "McArdle PA, Canna K, McMillan DC, McNicol AM, Campbell R, Underwood MA (2004) The relationship between T-lymphocyte subset infiltration and survival in patients with prostate cancer. Br J Cancer 91:541\u2013543", "journal-title": "Br J Cancer"}, {"key": "110_CR19", "doi-asserted-by": "crossref", "first-page": "280", "DOI": "10.1093/jnci/87.4.280", "volume": "87", "author": "MG Sanda", "year": "1995", "unstructured": "Sanda MG, Restifo NP, Walsh JC, Kawakami Y, Nelson WG, Pardoll DM, Simons JW (1995) Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst 87:280\u2013285", "journal-title": "J Natl Cancer Inst"}, {"key": "110_CR20", "doi-asserted-by": "crossref", "first-page": "233", "DOI": "10.1002/(SICI)1097-0045(19971201)33:4<233::AID-PROS2>3.0.CO;2-I", "volume": "33", "author": "NH Bander", "year": "1997", "unstructured": "Bander NH, Yao D, Liu H, Chen YT, Steiner M, Zuccaro W, Moy P (1997) MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma. Prostate 33:233\u2013239", "journal-title": "Prostate"}, {"key": "110_CR21", "doi-asserted-by": "crossref", "first-page": "168", "DOI": "10.1016/S1078-1439(00)00063-6", "volume": "5", "author": "M Abdul", "year": "2000", "unstructured": "Abdul M, Hoosein N (2000) Changes in beta-2 microglobulin expression in prostate cancer. Urol Oncol 5:168\u2013172", "journal-title": "Urol Oncol"}, {"key": "110_CR22", "first-page": "1927", "volume": "60", "author": "HM Lee", "year": "2000", "unstructured": "Lee HM, Timme TL, Thompson TC (2000) Resistance to lysis by cytotoxic T cells: a dominant effect in metastatic mouse prostate cancer cells. Cancer Res 60:1927\u20131933", "journal-title": "Cancer Res"}, {"key": "110_CR23", "doi-asserted-by": "crossref", "first-page": "6719", "DOI": "10.1073/pnas.86.17.6719", "volume": "86", "author": "PG Natali", "year": "1989", "unstructured": "Natali PG, Nicotra MR, Bigotti A, Venturo I, Marcenaro L, Giacomini P, Russo C (1989) Selective changes in expression of HLA class I polymorphic determinants in human solid tumors. Proc Natl Acad Sci USA 86:6719\u20136723", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "110_CR24", "unstructured": "Blades RA, Keating PJ, McWilliam LJ, George NJ, Stern PL (1995) Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Urology 46:681\u2013686; discussion 686\u2013687", "DOI": "10.1016/S0090-4295(99)80301-X", "doi-asserted-by": "crossref"}, {"key": "110_CR25", "first-page": "2", "volume": "3", "author": "H Zhang", "year": "2003", "unstructured": "Zhang H, Melamed J, Wei P, Cox K, Frankel W, Bahnson RR, Robinson N, Pyka R, Liu Y, Zheng P (2003) Concordant down-regulation of proto-oncogene PML and major histocompatibility antigen HLA class I expression in high-grade prostate cancer. Cancer Immun 3:2", "journal-title": "Cancer Immun"}, {"key": "110_CR26", "first-page": "223", "volume": "8", "author": "P Kidd", "year": "2003", "unstructured": "Kidd P (2003) Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern Med Rev 8:223\u2013246", "journal-title": "Altern Med Rev"}, {"key": "110_CR27", "doi-asserted-by": "crossref", "first-page": "271", "DOI": "10.1002/1097-0045(20000901)44:4<271::AID-PROS2>3.0.CO;2-G", "volume": "44", "author": "X Filella", "year": "2000", "unstructured": "Filella X, Alcover J, Zarco MA, Beardo P, Molina R, Ballesta AM (2000) Analysis of type T1 and T2 cytokines in patients with prostate cancer. Prostate 44:271\u2013274", "journal-title": "Prostate"}, {"key": "110_CR28", "doi-asserted-by": "crossref", "first-page": "722", "DOI": "10.1016/S0022-5347(05)67289-8", "volume": "164", "author": "GJ Wise", "year": "2000", "unstructured": "Wise GJ, Marella VK, Talluri G, Shirazian D (2000) Cytokine variations in patients with hormone treated prostate cancer. J Urol 164:722\u2013725", "journal-title": "J Urol"}, {"key": "110_CR29", "first-page": "4027", "volume": "23", "author": "U Elsasser-Beile", "year": "2003", "unstructured": "Elsasser-Beile U, Gierschner D, Jantscheff P, Schultze-Seemann W, Katzenwadel A, Wetterauer U (2003) Different basal expression of type T1 and T2 cytokines in peripheral lymphocytes of patients with adenocarcinomas and benign hyperplasia of the prostate. Anticancer Res 23:4027\u20134031", "journal-title": "Anticancer Res"}, {"key": "110_CR30", "doi-asserted-by": "crossref", "first-page": "182", "DOI": "10.1016/S0022-5347(01)62092-5", "volume": "161", "author": "HL Adler", "year": "1999", "unstructured": "Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC (1999) Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol 161:182\u2013187", "journal-title": "J Urol"}, {"key": "110_CR31", "doi-asserted-by": "crossref", "first-page": "127", "DOI": "10.1002/(SICI)1097-0045(19991001)41:2<127::AID-PROS7>3.0.CO;2-H", "volume": "41", "author": "DE Drachenberg", "year": "1999", "unstructured": "Drachenberg DE, Elgamal AA, Rowbotham R, Peterson M, Murphy GP (1999) Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 41:127\u2013133", "journal-title": "Prostate"}, {"key": "110_CR32", "first-page": "2702", "volume": "6", "author": "J Nakashima", "year": "2000", "unstructured": "Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H, Murai M (2000) Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 6:2702\u20132706", "journal-title": "Clin Cancer Res"}, {"key": "110_CR33", "doi-asserted-by": "crossref", "first-page": "497", "DOI": "10.1002/jcb.20477", "volume": "95", "author": "Z Culig", "year": "2005", "unstructured": "Culig Z, Steiner H, Bartsch G, Hobisch A (2005) Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem 95:497\u2013505", "journal-title": "J Cell Biochem"}, {"key": "110_CR34", "doi-asserted-by": "crossref", "first-page": "94", "DOI": "10.1016/j.clim.2005.06.011", "volume": "117", "author": "SM Perambakam", "year": "2005", "unstructured": "Perambakam SM, Srivastava R, Peace DJ (2005) Distinct cytokine patterns exist in peripheral blood mononuclear cell cultures of patients with prostate cancer. Clin Immunol 117:94\u201399", "journal-title": "Clin Immunol"}, {"key": "110_CR35", "doi-asserted-by": "crossref", "first-page": "1", "DOI": "10.1002/1097-0045(20000915)45:1<1::AID-PROS1>3.0.CO;2-V", "volume": "45", "author": "U Elsasser-Beile", "year": "2000", "unstructured": "Elsasser-Beile U, Przytulski B, Gierschner D, Grussenmeyer T, Katzenwadel A, Leiber C, Deckart A, Wetterauer U (2000) Comparison of the activation status of tumor infiltrating and peripheral lymphocytes of patients with adenocarcinomas and benign hyperplasia of the prostate. Prostate 45:1\u20137", "journal-title": "Prostate"}, {"key": "110_CR36", "first-page": "1", "volume": "22", "author": "MR Cardillo", "year": "2000", "unstructured": "Cardillo MR, Petrangeli E, Perracchio L, Salvatori L, Ravenna L, Di Silverio F (2000) Transforming growth factor-beta expression in prostate neoplasia. Anal Quant Cytol Histol 22:1\u201310", "journal-title": "Anal Quant Cytol Histol"}, {"key": "110_CR37", "first-page": "3823", "volume": "20", "author": "K Stravodimos", "year": "2000", "unstructured": "Stravodimos K, Constantinides C, Manousakas T, Pavlaki C, Pantazopoulos D, Giannopoulos A, Dimopoulos C (2000) Immunohistochemical expression of transforming growth factor beta 1 and nm-23 H1 antioncogene in prostate cancer: divergent correlation with clinicopathological parameters. Anticancer Res 20:3823\u20133828", "journal-title": "Anticancer Res"}, {"key": "110_CR38", "doi-asserted-by": "crossref", "first-page": "1992", "DOI": "10.1158/1078-0432.CCR-0768-03", "volume": "10", "author": "SF Shariat", "year": "2004", "unstructured": "Shariat SF, Kattan MW, Traxel E, Andrews B, Zhu K, Wheeler TM, Slawin KM (2004) Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression. Clin Cancer Res 10:1992\u20131999", "journal-title": "Clin Cancer Res"}, {"key": "110_CR39", "doi-asserted-by": "crossref", "first-page": "435", "DOI": "10.1016/S0090-4295(99)80012-0", "volume": "45", "author": "AL Burnett", "year": "1995", "unstructured": "Burnett AL, Maguire MP, Chamness SL, Ricker DD, Takeda M, Lepor H, Chang TS (1995) Characterization and localization of nitric oxide synthase in the human prostate. Urology 45:435\u2013439", "journal-title": "Urology"}, {"key": "110_CR40", "doi-asserted-by": "crossref", "first-page": "1", "DOI": "10.1002/(SICI)1097-0045(19970915)33:1<1::AID-PROS1>3.0.CO;2-P", "volume": "33", "author": "W Bloch", "year": "1997", "unstructured": "Bloch W, Klotz T, Loch C, Schmidt G, Engelmann U, Addicks K (1997) Distribution of nitric oxide synthase implies a regulation of circulation, smooth muscle tone, and secretory function in the human prostate by nitric oxide. Prostate 33:1\u20138", "journal-title": "Prostate"}, {"key": "110_CR41", "doi-asserted-by": "crossref", "first-page": "23", "DOI": "10.1007/s002400000148", "volume": "29", "author": "P Uotila", "year": "2001", "unstructured": "Uotila P, Valve E, Martikainen P, Nevalainen M, Nurmi M Harkonen P (2001) Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer. Urol Res 29:23\u201328", "journal-title": "Urol Res"}, {"key": "110_CR42", "doi-asserted-by": "crossref", "first-page": "117", "DOI": "10.1016/S1078-1439(02)00208-9", "volume": "21", "author": "J Wang", "year": "2003", "unstructured": "Wang J, Torbenson M, Wang Q, Ro JY, Becich M (2003) Expression of inducible nitric oxide synthase in paired neoplastic and non-neoplastic primary prostate cell cultures and prostatectomy specimen. Urol Oncol 21:117\u2013122", "journal-title": "Urol Oncol"}, {"key": "110_CR43", "doi-asserted-by": "crossref", "first-page": "1897", "DOI": "10.1002/(SICI)1097-0142(19980515)82:10<1897::AID-CNCR12>3.0.CO;2-O", "volume": "82", "author": "T Klotz", "year": "1998", "unstructured": "Klotz T, Bloch W, Volberg C, Engelmann U, Addicks K (1998) Selective expression of inducible nitric oxide synthase in human prostate carcinoma. Cancer 82:1897\u20131903", "journal-title": "Cancer"}, {"issue": "8", "key": "110_CR44", "doi-asserted-by": "crossref", "first-page": "1257", "DOI": "10.1084/jem.20042028", "volume": "201", "author": "V Bronte", "year": "2005", "unstructured": "Bronte V, Kasic T, Gri G, Gallana K, Borsellino G, Marigo I, Battistini L, Iafrate M, Prayer-Galetti T, Pagano F et al (2005) Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med 201(8):1257\u20131268", "journal-title": "J Exp Med"}, {"key": "110_CR45", "first-page": "3008", "volume": "43", "author": "BE Harris", "year": "1983", "unstructured": "Harris BE, Pretlow TP, Bradley EL Jr, Whitehurst GB, Pretlow TG II (1983) Arginase activity in prostatic tissue of patients with benign prostatic hyperplasia and prostatic carcinoma. Cancer Res 43:3008\u20133012", "journal-title": "Cancer Res"}, {"key": "110_CR46", "first-page": "3101", "volume": "21", "author": "SH Aaltoma", "year": "2001", "unstructured": "Aaltoma SH, Lipponen PK, Kosma VM (2001) Inducible nitric oxide synthase (iNOS) expression and its prognostic value in prostate cancer. Anticancer Res 21:3101\u20133106", "journal-title": "Anticancer Res"}, {"key": "110_CR47", "doi-asserted-by": "crossref", "first-page": "311", "DOI": "10.1038/sj.cr.7290133", "volume": "12", "author": "W Xu", "year": "2002", "unstructured": "Xu W, Liu LZ, Loizidou M, Ahmed M, Charles IG (2002) The role of nitric oxide in cancer. Cell Res 12:311\u2013320", "journal-title": "Cell Res"}, {"key": "110_CR48", "doi-asserted-by": "crossref", "first-page": "641", "DOI": "10.1038/nri1668", "volume": "5", "author": "V Bronte", "year": "2005", "unstructured": "Bronte V, Zanovello P (2005) Regulation of immune responses by l-arginine metabolism. Nat Rev Immunol 5:641\u2013654", "journal-title": "Nat Rev Immunol"}, {"key": "110_CR49", "doi-asserted-by": "crossref", "first-page": "20", "DOI": "10.1016/j.bbrc.2005.08.232", "volume": "338", "author": "A Mellor", "year": "2005", "unstructured": "Mellor A (2005) Indoleamine 2,3 dioxygenase and regulation of T cell immunity. Biochem Biophys Res Commun 338:20\u201324", "journal-title": "Biochem Biophys Res Commun"}, {"key": "110_CR50", "doi-asserted-by": "crossref", "first-page": "127", "DOI": "10.1016/S0090-4295(01)01255-9", "volume": "58", "author": "A Kirschenbaum", "year": "2001", "unstructured": "Kirschenbaum A, Liu X, Yao S, Levine AC (2001) The role of cyclooxygenase-2 in prostate cancer. Urology 58:127\u2013131", "journal-title": "Urology"}, {"key": "110_CR51", "doi-asserted-by": "crossref", "first-page": "3250", "DOI": "10.1158/1078-0432.CCR-04-2405", "volume": "11", "author": "W Wang", "year": "2005", "unstructured": "Wang W, Bergh A, Damber JE (2005) Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer. Clin Cancer Res 11:3250\u20133256", "journal-title": "Clin Cancer Res"}, {"key": "110_CR52", "doi-asserted-by": "crossref", "first-page": "451", "DOI": "10.1046/j.1464-410x.2000.00507.x", "volume": "85", "author": "AF Badawi", "year": "2000", "unstructured": "Badawi AF (2000) The role of prostaglandin synthesis in prostate cancer. BJU Int 85:451\u2013462", "journal-title": "BJU Int"}, {"key": "110_CR53", "doi-asserted-by": "crossref", "first-page": "721", "DOI": "10.1002/(SICI)1097-0215(19990827)82:5<721::AID-IJC16>3.0.CO;2-N", "volume": "82", "author": "AK Chan", "year": "1999", "unstructured": "Chan AK, Lockhart DC, von Bernstorff W, Spanjaard RA, Joo HG, Eberlein TJ, Goedegebuure PS (1999) Soluble MUC1 secreted by human epithelial cancer cells mediates immune suppression by blocking T-cell activation. Int J Cancer 82:721\u2013726", "journal-title": "Int J Cancer"}, {"key": "110_CR54", "doi-asserted-by": "crossref", "first-page": "7764", "DOI": "10.4049/jimmunol.174.12.7764", "volume": "174", "author": "A. Rughetti", "year": "2005", "unstructured": "Rughetti A, Pellicciotta I, Biffoni M, Backstrom M, Link T, Bennet EP, Clausen H, Noll T, Hansson GC, Burchell JM et al (2005) Recombinant tumor-associated MUC1 glycoprotein impairs the differentiation and function of dendritic cells. J Immunol 174:7764\u20137772", "journal-title": "J Immunol"}, {"key": "110_CR55", "first-page": "163", "volume": "3", "author": "A Kirschenbaum", "year": "1999", "unstructured": "Kirschenbaum A, Itzkowitz SH, Wang JP, Yao S, Eliashvili M, Levine AC (1999) MUC1 expression in prostate carcinoma: correlation with grade and stage. Mol Urol 3:163\u2013168", "journal-title": "Mol Urol"}, {"key": "110_CR56", "doi-asserted-by": "crossref", "first-page": "811", "DOI": "10.1073/pnas.0304146101", "volume": "101", "author": "J Lapointe", "year": "2004", "unstructured": "Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U et al (2004) Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 101:811\u2013816", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "110_CR57", "doi-asserted-by": "crossref", "first-page": "654", "DOI": "10.1111/j.1442-2042.2005.01112.x", "volume": "12", "author": "T Arai", "year": "2005", "unstructured": "Arai T, Fujita K, Fujime M, Irimura T (2005) Expression of sialylated MUC1 in prostate cancer: relationship to clinical stage and prognosis. Int J Urol 12:654\u2013661", "journal-title": "Int J Urol"}, {"key": "110_CR58", "doi-asserted-by": "crossref", "first-page": "741", "DOI": "10.1016/S0022-5347(05)64738-6", "volume": "168", "author": "AG Kennedy-Smith", "year": "2002", "unstructured": "Kennedy-Smith AG, McKenzie JL, Owen MC, Davidson PJ, Vuckovic S, Hart DN (2002) Prostate specific antigen inhibits immune responses in vitro: a potential role in prostate cancer. J Urol 168:741\u2013747", "journal-title": "J Urol"}, {"key": "110_CR59", "doi-asserted-by": "crossref", "first-page": "2026", "DOI": "10.1097/01.ju.0000091264.46134.b7", "volume": "170", "author": "M Aalamian", "year": "2003", "unstructured": "Aalamian M, Tourkova IL, Chatta GS, Lilja H, Huland E, Huland H, Shurin GV, Shurin MR (2003) Inhibition of dendropoiesis by tumor derived and purified prostate specific antigen. J Urol 170:2026\u20132030", "journal-title": "J Urol"}, {"key": "110_CR60", "doi-asserted-by": "crossref", "first-page": "809", "DOI": "10.2741/1575", "volume": "10", "author": "SI Abrams", "year": "2005", "unstructured": "Abrams SI (2005) Positive and negative consequences of Fas/Fas ligand interactions in the antitumor response. Front Biosci 10:809\u2013821", "journal-title": "Front Biosci"}, {"key": "110_CR61", "first-page": "3595", "volume": "21", "author": "Y Furuya", "year": "2001", "unstructured": "Furuya Y, Fuse H, Masai M (2001) Serum soluble Fas level for detection and staging of prostate cancer. Anticancer Res 21:3595\u20133598", "journal-title": "Anticancer Res"}, {"key": "110_CR62", "first-page": "1803", "volume": "4", "author": "QY Liu", "year": "1998", "unstructured": "Liu QY, Rubin MA, Omene C, Lederman S, Stein CA (1998) Fas ligand is constitutively secreted by prostate cancer cells in vitro. Clin Cancer Res 4:1803\u20131811", "journal-title": "Clin Cancer Res"}, {"key": "110_CR63", "doi-asserted-by": "crossref", "first-page": "169", "DOI": "10.1016/j.bcmd.2005.07.001", "volume": "35", "author": "AJ Abusamra", "year": "2005", "unstructured": "Abusamra AJ, Zhong Z, Zheng X, Li M, Ichim TE, Chin JL, Min WP (2005) Tumor exosomes expressing Fas ligand mediate CD8(+) T-cell apoptosis. Blood Cells Mol Dis 35:169\u2013173", "journal-title": "Blood Cells Mol Dis"}, {"key": "110_CR64", "first-page": "3273", "volume": "162", "author": "TZ Zaks", "year": "1999", "unstructured": "Zaks TZ, Chappell DB, Rosenberg SA, Restifo NP (1999) Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition. J Immunol 162:3273\u20133279", "journal-title": "J Immunol"}, {"key": "110_CR65", "doi-asserted-by": "crossref", "first-page": "493", "DOI": "10.1038/74955", "volume": "6", "author": "NP Restifo", "year": "2000", "unstructured": "Restifo NP (2000) Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape. Nat Med 6:493\u2013495", "journal-title": "Nat Med"}, {"key": "110_CR66", "doi-asserted-by": "crossref", "first-page": "13", "DOI": "10.1097/00002371-200401000-00002", "volume": "27", "author": "RP Ciavarra", "year": "2004", "unstructured": "Ciavarra RP, Holterman DA, Brown RR, Mangiotti P, Yousefieh N, Wright GL Jr, Schellhammer PF, Glass WF, Somers KD (2004) Prostate tumor microenvironment alters immune cells and prevents long-term survival in an orthotopic mouse model following flt3-ligand/CD40-ligand immunotherapy. J Immunother 27:13\u201326", "journal-title": "J Immunother"}, {"key": "110_CR67", "doi-asserted-by": "crossref", "first-page": "109", "DOI": "10.1002/(SICI)1097-0320(19980601)32:2<109::AID-CYTO6>3.0.CO;2-G", "volume": "32", "author": "CG Healy", "year": "1998", "unstructured": "Healy CG, Simons JW, Carducci MA, DeWeese TL, Bartkowski M, Tong KP, Bolton WE (1998) Impaired expression and function of signal-transducing zeta chains in peripheral T cells and natural killer cells in patients with prostate cancer. Cytometry 32:109\u2013119", "journal-title": "Cytometry"}, {"key": "110_CR68", "doi-asserted-by": "crossref", "first-page": "168", "DOI": "10.1038/sj.bjc.6600039", "volume": "86", "author": "N Meidenbauer", "year": "2002", "unstructured": "Meidenbauer N, Gooding W, Spitler L, Harris D, Whiteside TL (2002) Recovery of zeta-chain expression and changes in spontaneous IL-10 production after PSA-based vaccines in patients with prostate cancer. Br J Cancer 86:168\u2013178", "journal-title": "Br J Cancer"}, {"key": "110_CR69", "doi-asserted-by": "crossref", "first-page": "809", "DOI": "10.1111/j.1365-2141.2005.05627.x", "volume": "130", "author": "KS Peggs", "year": "2005", "unstructured": "Peggs KS, Allison JP (2005) Co-stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamily. Br J Haematol 130:809\u2013824", "journal-title": "Br J Haematol"}, {"key": "110_CR70", "doi-asserted-by": "crossref", "first-page": "8099", "DOI": "10.1073/pnas.94.15.8099", "volume": "94", "author": "ED Kwon", "year": "1997", "unstructured": "Kwon ED, Hurwitz AA, Foster BA, Madias C, Feldhaus AL, Greenberg NM, Burg MB, Allison JP (1997) Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci USA 94:8099\u20138103", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "110_CR71", "first-page": "2444", "volume": "60", "author": "AA Hurwitz", "year": "2000", "unstructured": "Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, Greenberg NM, Burg MB, Allison JP (2000) Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 60:2444\u20132448", "journal-title": "Cancer Res"}, {"key": "110_CR72", "first-page": "4101", "volume": "6", "author": "GW Hull", "year": "2000", "unstructured": "Hull GW, McCurdy MA, Nasu Y, Bangma CH, Yang G, Shimura S, Lee HM, Wang J, Albani J, Ebara S, et al (2000) Prostate cancer gene therapy: comparison of adenovirus-mediated expression of interleukin 12 with interleukin 12 plus B7\u20131 for in situ gene therapy and gene-modified, cell-based vaccines. Clin Cancer Res 6:4101\u20134109", "journal-title": "Clin Cancer Res"}, {"key": "110_CR73", "doi-asserted-by": "crossref", "first-page": "245", "DOI": "10.1038/32588", "volume": "392", "author": "J Banchereau", "year": "1998", "unstructured": "Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392:245\u2013252", "journal-title": "Nature"}, {"key": "110_CR74", "doi-asserted-by": "crossref", "first-page": "445", "DOI": "10.1016/S1471-4906(02)02281-0", "volume": "23", "author": "MB Lutz", "year": "2002", "unstructured": "Lutz MB, Schuler G (2002) Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol 23:445\u2013449", "journal-title": "Trends Immunol"}, {"key": "110_CR75", "doi-asserted-by": "crossref", "first-page": "13", "DOI": "10.1016/S0065-230X(04)92002-7", "volume": "92", "author": "L Yang", "year": "2004", "unstructured": "Yang L, Carbone DP (2004) Tumor-host immune interactions and dendritic cell dysfunction. Adv Cancer Res 92:13\u201327", "journal-title": "Adv Cancer Res"}, {"key": "110_CR76", "doi-asserted-by": "crossref", "first-page": "214", "DOI": "10.1016/S0022-5347(01)63093-3", "volume": "160", "author": "A Troy", "year": "1998", "unstructured": "Troy A, Davidson P, Atkinson C, Hart D (1998) Phenotypic characterisation of the dendritic cell infiltrate in prostate cancer. J Urol 160:214\u2013219", "journal-title": "J Urol"}, {"key": "110_CR77", "doi-asserted-by": "crossref", "first-page": "68", "DOI": "10.1002/1097-0045(200101)46:1<68::AID-PROS1010>3.0.CO;2-2", "volume": "46", "author": "M Aalamian", "year": "2001", "unstructured": "Aalamian M, Pirtskhalaishvili G, Nunez A, Esche C, Shurin GV, Huland E, Huland H, Shurin MR (2001) Human prostate cancer regulates generation and maturation of monocyte-derived dendritic cells. Prostate 46:68\u201375", "journal-title": "Prostate"}, {"key": "110_CR78", "first-page": "37", "volume": "4", "author": "GV Shurin", "year": "2001", "unstructured": "Shurin GV, Aalamian M, Pirtskhalaishvili G, Bykovskaia S, Huland E, Huland H, Shurin MR (2001) Human prostate cancer blocks the generation of dendritic cells from CD34+ hematopoietic progenitors. Eur Urol 39 Suppl 4:37\u201340", "journal-title": "Eur Urol 39 Suppl"}, {"key": "110_CR79", "doi-asserted-by": "crossref", "first-page": "39", "DOI": "10.1002/(SICI)1097-0045(19980615)36:1<39::AID-PROS6>3.0.CO;2-6", "volume": "36", "author": "BA Tjoa", "year": "1998", "unstructured": "Tjoa BA, Simmons SJ, Bowes VA, Ragde H, Rogers M, Elgamal A, Kenny GM, Cobb OE, Ireton RC, Troychak MJ et al (1998) Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 36:39\u201344", "journal-title": "Prostate"}, {"key": "110_CR80", "doi-asserted-by": "crossref", "first-page": "453", "DOI": "10.1007/s00262-003-0451-2", "volume": "53", "author": "B Barrou", "year": "2004", "unstructured": "Barrou B, Benoit G, Ouldkaci M, Cussenot O, Salcedo M, Agrawal S, Massicard S, Bercovici N, Ericson ML, Thiounn N (2004) Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA. Cancer Immunol Immunother 53:453\u2013460", "journal-title": "Cancer Immunol Immunother"}, {"key": "110_CR81", "doi-asserted-by": "crossref", "first-page": "3894", "DOI": "10.1200/JCO.2000.18.23.3894", "volume": "18", "author": "EJ Small", "year": "2000", "unstructured": "Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, Valone FH (2000) Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 18:3894\u20133903", "journal-title": "J Clin Oncol"}, {"key": "110_CR82", "doi-asserted-by": "crossref", "first-page": "202", "DOI": "10.1097/00002371-200205000-00002", "volume": "25", "author": "PA Antony", "year": "2002", "unstructured": "Antony PA, Restifo NP (2002) Do CD4+ CD25+ immunoregulatory T cells hinder tumor immunotherapy? J Immunother 25:202\u2013206", "journal-title": "J Immunother"}, {"key": "110_CR83", "first-page": "1151", "volume": "155", "author": "S Sakaguchi", "year": "1995", "unstructured": "Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155:1151\u20131164", "journal-title": "J Immunol"}, {"key": "110_CR84", "doi-asserted-by": "crossref", "first-page": "18", "DOI": "10.1034/j.1600-065X.2001.1820102.x", "volume": "182", "author": "S Sakaguchi", "year": "2001", "unstructured": "Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M, Kuniyasu Y, Nomura T, Toda M, Takahashi T (2001) Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 182:18\u201332", "journal-title": "Immunol Rev"}, {"key": "110_CR85", "doi-asserted-by": "crossref", "first-page": "2947", "DOI": "10.1158/0008-5472.CAN-04-3271", "volume": "65", "author": "AH Tien", "year": "2005", "unstructured": "Tien AH, Xu L, Helgason CD (2005) Altered immunity accompanies disease progression in a mouse model of prostate dysplasia. Cancer Res 65:2947\u20132955", "journal-title": "Cancer Res"}], "container-title": ["Cancer Immunology, Immunotherapy"], "language": "en", "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/s00262-005-0110-x.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/article/10.1007/s00262-005-0110-x/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/content/pdf/10.1007/s00262-005-0110-x", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 24]], "date-time": "2019-05-24T16:33:00Z", "timestamp": 1558715580000}, "score": 21.970444, "issued": {"date-parts": [[2005, 12, 16]]}, "references-count": 85, "journal-issue": {"published-print": {"date-parts": [[2006, 11, 6]]}, "issue": "1"}, "alternative-id": ["110"], "URL": "http://dx.doi.org/10.1007/s00262-005-0110-x", "relation": {"cites": []}, "ISSN": ["0340-7004", "1432-0851"], "issn-type": [{"value": "0340-7004", "type": "print"}, {"value": "1432-0851", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 12, 4]], "date-time": "2019-12-04T22:54:35Z", "timestamp": 1575500075745}, "reference-count": 128, "publisher": "SAGE Publications", "issue": "1", "license": [{"URL": "http://journals.sagepub.com/page/policies/text-and-data-mining-license", "start": {"date-parts": [[2019, 1, 1]], "date-time": "2019-01-01T00:00:00Z", "timestamp": 1546300800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": ["journals.sagepub.com"], "crossmark-restriction": true}, "short-container-title": ["Cancer Control"], "published-print": {"date-parts": [[2019, 1]]}, "abstract": "<jats:p> Colorectal cancer (CRC) is one of the most widely recognized and deadly malignancies worldwide. In spite of the fact that the death rates have declined over the previous decade, particularly because of enhanced screening or potential treatment alternatives, CRC still remains the third leading cause of cancer-related mortality in the world, with an estimated incidence of over 1 million new cases and approximately 600 000 deaths estimated yearly. Unlike prostate and lung cancer, CRC is not easily detectable in its early stage, which may also account for its high mortality rate. MicroRNAs (miRNAs) are a class of noncoding RNAs. The roles of these noncoding RNAs have been implicated in cancer pathogenesis, most especially CRC, due to their ability to posttranscriptionally regulate the expression of oncogenes and tumor suppressor genes. Dysregulated expression of many miRNAs regulates the expression of hundreds of growth regulatory genes and pathways that are important in the multistep model of colorectal carcinogenesis. If CRC is detected early, it is a largely treatable disease. Early diagnosis, including the identification of premalignant adenomas, is regarded a major concept for improving patient survival in CRC treatment. Several lines of research suggest that miRNAs are closely implicated in the metastatic process in CRC and some of these miRNAs could be useful as promising clinical tools for identifying specific stages of CRC due to their differential expression. This review discusses the correlation between CRC staging relative to the specific expression of miRNA for early detection, treatment, and disease management. </jats:p>", "DOI": "10.1177/1073274819862784", "type": "journal-article", "created": {"date-parts": [[2019, 8, 21]], "date-time": "2019-08-21T06:29:15Z", "timestamp": 1566368955000}, "page": "107327481986278", "update-policy": "http://dx.doi.org/10.1177/sage-journals-update-policy", "source": "Crossref", "is-referenced-by-count": 3, "title": ["Biomarkers for Stratification in Colorectal Cancer: MicroRNAs"], "prefix": "10.1177", "volume": "26", "author": [{"ORCID": "http://orcid.org/0000-0002-3952-2098", "authenticated-orcid": false, "given": "Adewale Oluwaseun", "family": "Fadaka", "sequence": "first", "affiliation": [{"name": "Department of Biotechnology, Faculty of Natural Sciences, University of the Western Cape, Cape Town, South Africa"}]}, {"given": "Ashley", "family": "Pretorius", "sequence": "additional", "affiliation": [{"name": "Department of Biotechnology, Faculty of Natural Sciences, University of the Western Cape, Cape Town, South Africa"}]}, {"given": "Ashwil", "family": "Klein", "sequence": "additional", "affiliation": [{"name": "Department of Biotechnology, Faculty of Natural Sciences, University of the Western Cape, Cape Town, South Africa"}]}], "member": "179", "published-online": {"date-parts": [[2019, 8, 20]]}, "reference": [{"key": "bibr1-1073274819862784", "author": "Arnold M", "year": "2016", "journal-title": "Gut"}, {"key": "bibr2-1073274819862784", "DOI": "10.7326/0003-4819-152-11-201006010-00002", "doi-asserted-by": "publisher"}, {"key": "bibr3-1073274819862784", "DOI": "10.3748/wjg.v20.i22.6786", "doi-asserted-by": "publisher"}, {"key": "bibr4-1073274819862784", "author": "Bosman FT", "first-page": "134", "year": "2010", "volume-title": "WHO Classification of Tumours of the Digestive System"}, {"issue": "3", "key": "bibr5-1073274819862784", "first-page": "153", "volume": "3", "author": "Fleming M", "year": "2012", "journal-title": "J Gastrointest Oncol"}, {"key": "bibr6-1073274819862784", "DOI": "10.1086/431213", "doi-asserted-by": "publisher"}, {"key": "bibr7-1073274819862784", "DOI": "10.1001/jama.293.16.1986", "doi-asserted-by": "publisher"}, {"key": "bibr8-1073274819862784", "DOI": "10.7150/jca.8871", "doi-asserted-by": "publisher"}, {"key": "bibr9-1073274819862784", "DOI": "10.1038/nature06913", "doi-asserted-by": "publisher"}, {"key": "bibr10-1073274819862784", "DOI": "10.1158/1055-9965.EPI-15-0578", "doi-asserted-by": "publisher"}, {"key": "bibr11-1073274819862784", "DOI": "10.1067/mcp.2001.113989", "doi-asserted-by": "publisher"}, {"key": "bibr12-1073274819862784", "DOI": "10.1111/j.1365-2125.2005.02435.x", "doi-asserted-by": "publisher"}, {"key": "bibr13-1073274819862784", "DOI": "10.1111/j.1463-1318.2010.02439.x", "doi-asserted-by": "publisher"}, {"key": "bibr14-1073274819862784", "DOI": "10.1586/erm.12.39", "doi-asserted-by": "publisher"}, {"key": "bibr15-1073274819862784", "DOI": "10.1158/0008-5472.CAN-07-6110", "doi-asserted-by": "publisher"}, {"issue": "4", "key": "bibr16-1073274819862784", "first-page": "161", "volume": "2", "author": "Ardekani AM", "year": "2010", "journal-title": "Avicenna J Med Biotechnol"}, {"key": "bibr17-1073274819862784", "DOI": "10.1002/wrna.1320", "doi-asserted-by": "publisher"}, {"key": "bibr18-1073274819862784", "DOI": "10.3892/ijo.2016.3503", "doi-asserted-by": "publisher"}, {"key": "bibr19-1073274819862784", "DOI": "10.1080/15476286.2016.1234658", "doi-asserted-by": "publisher"}, {"key": "bibr20-1073274819862784", "DOI": "10.1093/cvr/cvn156", "doi-asserted-by": "publisher"}, {"key": "bibr21-1073274819862784", "DOI": "10.1093/nar/gkw116", "doi-asserted-by": "publisher"}, {"key": "bibr22-1073274819862784", "DOI": "10.1016/j.addr.2014.09.001", "doi-asserted-by": "publisher"}, {"key": "bibr23-1073274819862784", "DOI": "10.1016/j.cca.2015.07.027", "doi-asserted-by": "publisher"}, {"issue": "7", "key": "bibr24-1073274819862784", "first-page": "1461", "volume": "6", "author": "Izzotti A", "year": "2016", "journal-title": "Am J Cancer Res"}, {"key": "bibr25-1073274819862784", "DOI": "10.1155/2012/873749", "doi-asserted-by": "publisher"}, {"key": "bibr26-1073274819862784", "DOI": "10.18632/oncotarget.12475", "doi-asserted-by": "publisher"}, {"key": "bibr27-1073274819862784", "DOI": "10.1016/j.biocel.2009.12.014", "doi-asserted-by": "publisher"}, {"key": "bibr28-1073274819862784", "DOI": "10.1038/cdd.2009.69", "doi-asserted-by": "publisher"}, {"key": "bibr29-1073274819862784", "DOI": "10.1016/j.canep.2011.05.002", "doi-asserted-by": "publisher"}, {"key": "bibr30-1073274819862784", "DOI": "10.1590/0100-69912017002004", "doi-asserted-by": "publisher"}, {"key": "bibr31-1073274819862784", "DOI": "10.1016/0092-8674(90)90186-I", "doi-asserted-by": "publisher"}, {"issue": "2", "key": "bibr32-1073274819862784", "first-page": "31", "volume": "31", "author": "Worthley DL", "year": "2010", "journal-title": "Clin Biochem Rev"}, {"key": "bibr33-1073274819862784", "DOI": "10.1056/NEJM199412223312507", "doi-asserted-by": "publisher"}, {"issue": "8", "key": "bibr34-1073274819862784", "first-page": "3230", "volume": "61", "author": "Loeb LA", "year": "2001", "journal-title": "Cancer Res"}, {"key": "bibr35-1073274819862784", "author": "Nojadeh JN", "volume": "17", "first-page": "159", "year": "2018", "journal-title": "EXCLI J"}, {"key": "bibr36-1073274819862784", "DOI": "10.1038/nrc1799", "doi-asserted-by": "publisher"}, {"key": "bibr37-1073274819862784", "DOI": "10.1073/pnas.97.2.710", "doi-asserted-by": "publisher"}, {"key": "bibr38-1073274819862784", "DOI": "10.1038/ng1834", "doi-asserted-by": "publisher"}, {"key": "bibr39-1073274819862784", "DOI": "10.1016/j.humpath.2006.10.005", "doi-asserted-by": "publisher"}, {"key": "bibr40-1073274819862784", "DOI": "10.1371/journal.pone.0003698", "doi-asserted-by": "publisher"}, {"key": "bibr41-1073274819862784", "DOI": "10.1186/s12935-018-0631-y", "doi-asserted-by": "publisher"}, {"key": "bibr42-1073274819862784", "DOI": "10.1111/j.1365-2141.2008.07077.x", "doi-asserted-by": "publisher"}, {"key": "bibr43-1073274819862784", "DOI": "10.1016/j.coph.2010.05.010", "doi-asserted-by": "publisher"}, {"key": "bibr44-1073274819862784", "DOI": "10.1002/ijc.25007", "doi-asserted-by": "publisher"}, {"key": "bibr45-1073274819862784", "DOI": "10.1038/nrclinonc.2011.76", "doi-asserted-by": "publisher"}, {"key": "bibr46-1073274819862784", "DOI": "10.3390/ijms12032055", "doi-asserted-by": "publisher"}, {"key": "bibr47-1073274819862784", "DOI": "10.1038/nrclinonc.2014.5", "doi-asserted-by": "publisher"}, {"key": "bibr48-1073274819862784", "DOI": "10.1016/j.bbrc.2014.08.001", "doi-asserted-by": "publisher"}, {"key": "bibr49-1073274819862784", "DOI": "10.4251/wjgo.v10.i7.145", "doi-asserted-by": "publisher"}, {"key": "bibr50-1073274819862784", "DOI": "10.1080/13543776.2017.1315103", "doi-asserted-by": "publisher"}, {"issue": "3", "key": "bibr51-1073274819862784", "first-page": "120", "volume": "6", "author": "Mojarad EN", "year": "2013", "journal-title": "Gastroenterol Hepatol Bed Bench"}, {"key": "bibr52-1073274819862784", "DOI": "10.1136/gut.2003.037671", "doi-asserted-by": "publisher"}, {"key": "bibr53-1073274819862784", "DOI": "10.1210/jc.2003-030305", "doi-asserted-by": "publisher"}, {"key": "bibr54-1073274819862784", "DOI": "10.1080/00313020801911512", "doi-asserted-by": "publisher"}, {"key": "bibr55-1073274819862784", "DOI": "10.1186/1476-4598-5-2", "doi-asserted-by": "publisher"}, {"key": "bibr56-1073274819862784", "DOI": "10.1210/jc.2008-0607", "doi-asserted-by": "publisher"}, {"key": "bibr57-1073274819862784", "DOI": "10.1210/jc.2003-031425", "doi-asserted-by": "publisher"}, {"key": "bibr58-1073274819862784", "DOI": "10.1093/jnci/djg123", "doi-asserted-by": "publisher"}, {"key": "bibr59-1073274819862784", "DOI": "10.1167/iovs.04-0093", "doi-asserted-by": "publisher"}, {"key": "bibr60-1073274819862784", "DOI": "10.1158/1078-0432.CCR-1118-3", "doi-asserted-by": "publisher"}, {"key": "bibr61-1073274819862784", "DOI": "10.2353/jmoldx.2006.060070", "doi-asserted-by": "publisher"}, {"key": "bibr62-1073274819862784", "DOI": "10.1186/1476-4598-5-2", "doi-asserted-by": "publisher"}, {"key": "bibr63-1073274819862784", "DOI": "10.1111/his.12055", "doi-asserted-by": "publisher"}, {"key": "bibr64-1073274819862784", "DOI": "10.1371/journal.pone.0013314", "doi-asserted-by": "publisher"}, {"key": "bibr65-1073274819862784", "DOI": "10.1038/nrclinonc.2009.237", "doi-asserted-by": "publisher"}, {"key": "bibr66-1073274819862784", "DOI": "10.1073/pnas.0804549105", "doi-asserted-by": "publisher"}, {"key": "bibr67-1073274819862784", "DOI": "10.1038/cr.2008.282", "doi-asserted-by": "publisher"}, {"key": "bibr68-1073274819862784", "DOI": "10.1093/nar/gkr254", "doi-asserted-by": "publisher"}, {"issue": "10", "key": "bibr69-1073274819862784", "first-page": "2614", "volume": "18", "author": "Jothimani G", "year": "2018", "journal-title": "Curr Top Med Chem"}, {"key": "bibr70-1073274819862784", "DOI": "10.1074/jbc.M110.107821", "doi-asserted-by": "publisher"}, {"key": "bibr71-1073274819862784", "DOI": "10.1073/pnas.1019055108", "doi-asserted-by": "publisher"}, {"key": "bibr72-1073274819862784", "DOI": "10.1038/ncb2210", "doi-asserted-by": "publisher"}, {"key": "bibr73-1073274819862784", "DOI": "10.1053/j.gastro.2012.03.008", "doi-asserted-by": "publisher"}, {"key": "bibr74-1073274819862784", "DOI": "10.3390/ijms17091459", "doi-asserted-by": "publisher"}, {"key": "bibr75-1073274819862784", "DOI": "10.1186/1476-4598-8-102", "doi-asserted-by": "publisher"}, {"key": "bibr76-1073274819862784", "DOI": "10.1038/nature03702", "doi-asserted-by": "publisher"}, {"key": "bibr77-1073274819862784", "DOI": "10.1159/000113489", "doi-asserted-by": "publisher"}, {"key": "bibr78-1073274819862784", "DOI": "10.1001/jama.299.4.425", "doi-asserted-by": "publisher"}, {"key": "bibr79-1073274819862784", "DOI": "10.1136/gut.2008.167817", "doi-asserted-by": "publisher"}, {"key": "bibr80-1073274819862784", "DOI": "10.1371/journal.pone.0017745", "doi-asserted-by": "publisher"}, {"key": "bibr81-1073274819862784", "DOI": "10.1371/journal.pone.0092921", "doi-asserted-by": "publisher"}, {"key": "bibr82-1073274819862784", "DOI": "10.1038/bjc.2013.819", "doi-asserted-by": "publisher"}, {"key": "bibr83-1073274819862784", "DOI": "10.1006/jbin.2002.1038", "doi-asserted-by": "publisher"}, {"key": "bibr84-1073274819862784", "DOI": "10.3748/wjg.v19.i44.8078", "doi-asserted-by": "publisher"}, {"key": "bibr85-1073274819862784", "DOI": "10.1186/1477-7819-12-370", "doi-asserted-by": "publisher"}, {"key": "bibr86-1073274819862784", "DOI": "10.1038/srep10645", "doi-asserted-by": "publisher"}, {"key": "bibr87-1073274819862784", "DOI": "10.1001/jamasurg.2014.3572", "doi-asserted-by": "publisher"}, {"key": "bibr88-1073274819862784", "DOI": "10.1371/journal.pone.0147383", "doi-asserted-by": "publisher"}, {"key": "bibr89-1073274819862784", "DOI": "10.1001/jamasurg.2016.5050", "doi-asserted-by": "publisher"}, {"key": "bibr90-1073274819862784", "author": "McShane LM", "year": "2005", "volume-title": "Identification of Clinically Useful Cancer Prognostic Factors: What are We Missing?"}, {"key": "bibr91-1073274819862784", "DOI": "10.1634/theoncologist.2012-0121", "doi-asserted-by": "publisher"}, {"key": "bibr92-1073274819862784", "DOI": "10.1016/j.critrevonc.2010.01.010", "doi-asserted-by": "publisher"}, {"key": "bibr93-1073274819862784", "DOI": "10.1016/j.ctrv.2015.06.007", "doi-asserted-by": "publisher"}, {"key": "bibr94-1073274819862784", "DOI": "10.1016/j.ejca.2010.05.009", "doi-asserted-by": "publisher"}, {"key": "bibr95-1073274819862784", "DOI": "10.1002/bjs.1800145312", "doi-asserted-by": "publisher"}, {"key": "bibr96-1073274819862784", "DOI": "10.1002/path.1700350303", "doi-asserted-by": "publisher"}, {"key": "bibr97-1073274819862784", "DOI": "10.1177/003591573703000412", "doi-asserted-by": "publisher"}, {"key": "bibr98-1073274819862784", "DOI": "10.1007/BF02236973", "doi-asserted-by": "publisher"}, {"issue": "5", "key": "bibr99-1073274819862784", "first-page": "367", "volume": "110", "author": "Hutter RV", "year": "1986", "journal-title": "Arch Pathol Lab Med"}, {"issue": "2", "key": "bibr100-1073274819862784", "first-page": "537", "volume": "52", "author": "Obrocea F", "year": "2011", "journal-title": "Rom J Morphol Embryol"}, {"key": "bibr101-1073274819862784", "DOI": "10.1038/bjc.2012.456", "doi-asserted-by": "publisher"}, {"issue": "9", "key": "bibr102-1073274819862784", "first-page": "1059", "volume": "30", "author": "Barresi V", "year": "2015", "journal-title": "Histol Histopathol"}, {"key": "bibr103-1073274819862784", "DOI": "10.1007/s00428-012-1326-8", "doi-asserted-by": "publisher"}, {"key": "bibr104-1073274819862784", "author": "Gospodarowicz MK", "year": "2017", "volume-title": "TNM Classification of Malignant Tumours"}, {"key": "bibr105-1073274819862784", "DOI": "10.1097/PAS.0b013e318263207c", "doi-asserted-by": "publisher"}, {"key": "bibr106-1073274819862784", "DOI": "10.3748/wjg.v16.i25.3103", "doi-asserted-by": "publisher"}, {"key": "bibr107-1073274819862784", "DOI": "10.1007/s00535-011-0520-9", "doi-asserted-by": "publisher"}, {"key": "bibr108-1073274819862784", "DOI": "10.3346/jkms.2015.30.1.16", "doi-asserted-by": "publisher"}, {"key": "bibr109-1073274819862784", "DOI": "10.1055/s-2007-984859", "doi-asserted-by": "publisher"}, {"issue": "1", "key": "bibr110-1073274819862784", "first-page": "19", "volume": "5", "author": "Armaghany T", "year": "2012", "journal-title": "Gastrointest Cancer Res"}, {"key": "bibr111-1073274819862784", "DOI": "10.1038/nm.3802", "doi-asserted-by": "publisher"}, {"key": "bibr112-1073274819862784", "DOI": "10.1200/JCO.2009.22.8858", "doi-asserted-by": "publisher"}, {"key": "bibr113-1073274819862784", "DOI": "10.1038/nrc2389", "doi-asserted-by": "publisher"}, {"key": "bibr114-1073274819862784", "DOI": "10.1007/978-1-4419-9967-2_1", "doi-asserted-by": "publisher"}, {"key": "bibr115-1073274819862784", "DOI": "10.1007/978-1-4020-6784-6_4", "doi-asserted-by": "publisher"}, {"key": "bibr116-1073274819862784", "DOI": "10.1158/1078-0432.CCR-12-0707", "doi-asserted-by": "publisher"}, {"key": "bibr117-1073274819862784", "DOI": "10.1073/pnas.0511155103", "doi-asserted-by": "publisher"}, {"key": "bibr118-1073274819862784", "DOI": "10.1073/pnas.0510565103", "doi-asserted-by": "publisher"}, {"key": "bibr119-1073274819862784", "DOI": "10.1158/1055-9965.EPI-11-0035", "doi-asserted-by": "publisher"}, {"key": "bibr120-1073274819862784", "DOI": "10.1097/PPO.0b013e318258b78f", "doi-asserted-by": "publisher"}, {"issue": "12", "key": "bibr121-1073274819862784", "first-page": "882", "volume": "1", "author": "Michael MZ", "year": "2003", "journal-title": "Mol Cancer Res"}, {"key": "bibr122-1073274819862784", "DOI": "10.1371/journal.pone.0087451", "doi-asserted-by": "publisher"}, {"key": "bibr123-1073274819862784", "DOI": "10.1186/s12885-017-3739-x", "doi-asserted-by": "publisher"}, {"key": "bibr124-1073274819862784", "DOI": "10.18632/oncotarget.14344", "doi-asserted-by": "publisher"}, {"key": "bibr125-1073274819862784", "DOI": "10.1111/j.1440-1746.2010.06417.x", "doi-asserted-by": "publisher"}, {"key": "bibr126-1073274819862784", "DOI": "10.1158/1940-6207.CAPR-10-0036", "doi-asserted-by": "publisher"}, {"key": "bibr127-1073274819862784", "DOI": "10.1158/1055-9965.EPI-10-0027", "doi-asserted-by": "publisher"}, {"key": "bibr128-1073274819862784", "DOI": "10.1038/srep16103", "doi-asserted-by": "publisher"}], "container-title": ["Cancer Control"], "language": "en", "link": [{"URL": "http://journals.sagepub.com/doi/pdf/10.1177/1073274819862784", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://journals.sagepub.com/doi/full-xml/10.1177/1073274819862784", "content-type": "application/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://journals.sagepub.com/doi/pdf/10.1177/1073274819862784", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 8, 21]], "date-time": "2019-08-21T06:29:32Z", "timestamp": 1566368972000}, "score": 21.891912, "issued": {"date-parts": [[2019, 1]]}, "references-count": 128, "journal-issue": {"published-online": {"date-parts": [[2019, 8, 20]]}, "published-print": {"date-parts": [[2019, 1]]}, "issue": "1"}, "alternative-id": ["10.1177/1073274819862784"], "URL": "http://dx.doi.org/10.1177/1073274819862784", "relation": {"cites": []}, "ISSN": ["1073-2748", "1073-2748"], "issn-type": [{"value": "1073-2748", "type": "print"}, {"value": "1073-2748", "type": "electronic"}], "subject": ["Oncology", "Hematology", "General Medicine"]}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T23:10:15Z", "timestamp": 1574464215210}, "publisher-location": "New York, NY", "reference-count": 73, "publisher": "Springer New York", "isbn-type": [{"value": "9781603278317", "type": "print"}, {"value": "9781603278294", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2010]]}, "DOI": "10.1007/978-1-60327-829-4_14", "type": "book-chapter", "created": {"date-parts": [[2010, 9, 13]], "date-time": "2010-09-13T18:40:40Z", "timestamp": 1284403240000}, "page": "153-161", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Platinum Agents in Prostate Cancer"], "prefix": "10.1007", "author": [{"given": "Ashley", "family": "Brick", "sequence": "first", "affiliation": []}, {"given": "Junyang", "family": "Niu", "sequence": "additional", "affiliation": []}, {"given": "Jiaoti", "family": "Huang", "sequence": "additional", "affiliation": []}, {"given": "William K.", "family": "Oh", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2010, 8, 3]]}, "reference": [{"key": "14_CR1_14", "doi-asserted-by": "publisher", "first-page": "1513", "DOI": "10.1056/NEJMoa041318", "volume": "351", "author": "DP Petrylak", "year": "2004", "unstructured": "Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513\u201320.", "journal-title": "N Engl J Med"}, {"key": "14_CR2_14", "doi-asserted-by": "publisher", "first-page": "1502", "DOI": "10.1056/NEJMoa040720", "volume": "351", "author": "IF Tannock", "year": "2004", "unstructured": "Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502\u201312.", "journal-title": "N Engl J Med"}, {"issue": "12", "key": "14_CR3_14", "doi-asserted-by": "publisher", "first-page": "650", "DOI": "10.1038/ncpuro1232", "volume": "5", "author": "JE Rosenberg", "year": "2008", "unstructured": "Rosenberg JE, Oh WK. What is the current status of second-line chemotherapy for castration-resistant prostate cancer? Nat Clin Pract Urol 2008;5(12):650\u20131.", "journal-title": "Nat Clin Pract Urol"}, {"issue": "3", "key": "14_CR4_14", "doi-asserted-by": "publisher", "first-page": "477", "DOI": "10.1002/cncr.22439", "volume": "109", "author": "WK Oh", "year": "2007", "unstructured": "Oh WK, Tay M, Huang J. Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer? Cancer 2007;109(3):477\u201386.", "journal-title": "Cancer"}, {"key": "14_CR5_14", "doi-asserted-by": "publisher", "first-page": "2", "DOI": "10.1159/000084201", "volume": "68", "author": "CN Sternberg", "year": "2005", "unstructured": "Sternberg CN, Whelan P, Hetherington J, et al. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology 2005;68:2\u20139.", "journal-title": "Oncology"}, {"key": "14_CR6_14", "author": "HB Breitz", "year": "2008", "unstructured": "Breitz HB, Roman LA, Karlov PA, et al. A phase II study of picoplatin with docetaxel and prednisone in chemotherapy-na\u00efve patients with metastatic hormone refractory prostate cancer (CRPC). J Clin Oncol 2008; 26 (May 20 Suppl; abstr 5153).", "volume-title": "A phase II study of picoplatin with docetaxel and prednisone in chemotherapy-na\u00efve patients with metastatic hormone refractory prostate cancer (CRPC). J Clin Oncol"}, {"key": "14_CR7_14", "doi-asserted-by": "publisher", "first-page": "1033", "DOI": "10.1517/13543784.14.8.1033", "volume": "14", "author": "MJ McKeage", "year": "2005", "unstructured": "McKeage MJ. New-generation platinum drugs in the treatment of cisplatin-resistant cancers. Expert Opin Investig Drugs 2005;14:1033\u201346.", "journal-title": "Expert Opin Investig Drugs"}, {"key": "14_CR8_14", "doi-asserted-by": "publisher", "first-page": "287", "DOI": "10.1016/0046-8177(92)90110-O", "volume": "23", "author": "PA Sant\u2019Agnese di", "year": "1992", "unstructured": "di Sant\u2019Agnese PA. Neuroendocrine differentiation in human prostatic carcinoma. Hum Pathol 1992;23:287\u201396.", "journal-title": "Hum Pathol"}, {"key": "14_CR9_14", "author": "J Huang", "first-page": "243", "year": "2002", "unstructured": "Huang J, diSant\u2019Agnese PA. Neuroendocrine differentiation in prostate cancer: an overview. In: Lamberts S, editor. Advances in Oncology: The Expanding Role of Octreotide. Bristol: BioScientifica Ltd; 2002. p. 243\u201362.", "volume-title": "Advances in Oncology: The Expanding Role of Octreotide"}, {"key": "14_CR10_14", "doi-asserted-by": "publisher", "first-page": "705", "DOI": "10.1097/00000478-200606000-00005", "volume": "30", "author": "JL Yao", "year": "2006", "unstructured": "Yao JL, Madeb R, Bourne P, et al. Small cell carcinoma of the prostate: an immunohistochemical study. Am J Surg Pathol 2006;30:705\u201312.", "journal-title": "Am J Surg Pathol"}, {"key": "14_CR11_14", "doi-asserted-by": "publisher", "first-page": "65", "DOI": "10.1097/PAS.0b013e318058a96b", "volume": "32", "author": "W Wang", "year": "2008", "unstructured": "Wang W, Epstein JI. Small cell carcinoma of the prostate: a morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol 2008;32:65\u201371.", "journal-title": "Am J Surg Pathol"}, {"key": "14_CR12_14", "doi-asserted-by": "publisher", "first-page": "684", "DOI": "10.1097/00000478-200606000-00003", "volume": "30", "author": "AJ Evans", "year": "2006", "unstructured": "Evans AJ, Humphrey PA, Belani J, van der Kwast TH, Srigley JR. Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer. Am J Surg Pathol 2006;30:684\u201393.", "journal-title": "Am J Surg Pathol"}, {"key": "14_CR13_14", "doi-asserted-by": "publisher", "first-page": "174", "DOI": "10.1016/j.urology.2004.07.010", "volume": "65", "author": "KH Lim", "year": "2005", "unstructured": "Lim KH, Huang MJ, Yang S, Hsieh RK, Lin J. Primary carcinoid tumor of prostate presenting with bone marrow metastases. Urology 2005;65:174.", "journal-title": "Urology"}, {"key": "14_CR14_14", "first-page": "e166", "volume": "128", "author": "A Reyes", "year": "2004", "unstructured": "Reyes A, Moran CA. Low-grade neuroendocrine carcinoma (carcinoid tumor) of the prostate. Arch Pathol Lab Med 2004;128:e166\u20138.", "journal-title": "Arch Pathol Lab Med"}, {"key": "14_CR15_14", "doi-asserted-by": "publisher", "first-page": "167", "DOI": "10.1177/106689690401200214", "volume": "12", "author": "JE Ghannoum", "year": "2004", "unstructured": "Ghannoum JE, DeLellis RA, Shin SJ. Primary carcinoid tumor of the prostate with concurrent adenocarcinoma: a case report. Int J Surg Pathol 2004;12:167\u201370.", "journal-title": "Int J Surg Pathol"}, {"key": "14_CR16_14", "doi-asserted-by": "publisher", "first-page": "373", "DOI": "10.1016/S0344-0338(89)80016-0", "volume": "185", "author": "PA Abrahamsson", "year": "1989", "unstructured": "Abrahamsson PA, Falkmer S, Falt K, Grimelius L. The course of neuroendocrine differentiation in prostatic carcinomas. An immunohistochemical study testing chromogranin A as an \u201cendocrine marker\u201d. Pathol Res Pract 1989;185:373\u201380.", "journal-title": "Pathol Res Pract"}, {"key": "14_CR17_14", "doi-asserted-by": "publisher", "first-page": "298", "DOI": "10.1016/S0344-0338(87)80065-1", "volume": "182", "author": "PA Abrahamsson", "year": "1987", "unstructured": "Abrahamsson PA, Wadstrom LB, Alumets J, Falkmer S, Grimelius L. Peptide-hormone- and serotonin-immunoreactive tumour cells in carcinoma of the prostate. Pathol Res Pract 1987;182:298\u2013307.", "journal-title": "Pathol Res Pract"}, {"key": "14_CR18_14", "doi-asserted-by": "publisher", "first-page": "1399", "DOI": "10.1002/pros.20434", "volume": "66", "author": "J Huang", "year": "2006", "unstructured": "Huang J, Yao JL, di Sant\u2019agnese PA, Yang Q, Bourne PA, Na Y. Immunohistochemical characterization of neuroendocrine cells in prostate cancer. Prostate 2006;66:1399\u2013406.", "journal-title": "Prostate"}, {"key": "14_CR23_14", "doi-asserted-by": "publisher", "first-page": "215", "DOI": "10.1016/j.eururo.2005.03.018", "volume": "48", "author": "L Puccetti", "year": "2005", "unstructured": "Puccetti L, Supuran CT, Fasolo PP, et al. Skewing towards neuroendocrine phenotype in high grade or high stage androgen-responsive primary prostate cancer. Eur Urol 2005;48:215\u201321; discussion 21\u20133.", "journal-title": "Eur Urol"}, {"key": "14_CR24_14", "doi-asserted-by": "publisher", "first-page": "2590", "DOI": "10.1002/1097-0142(20000601)88:11<2590::AID-CNCR23>3.0.CO;2-D", "volume": "88", "author": "A Berruti", "year": "2000", "unstructured": "Berruti A, Dogliotti L, Mosca A, et al. Circulating neuroendocrine markers in patients with prostate carcinoma. Cancer 2000;88:2590\u20137.", "journal-title": "Cancer"}, {"key": "14_CR25_14", "doi-asserted-by": "publisher", "first-page": "897", "DOI": "10.1016/j.urology.2005.04.064", "volume": "66", "author": "VE Theodoropoulos", "year": "2005", "unstructured": "Theodoropoulos VE, Tsigka A, Mihalopoulou A, et al. Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications. Urology 2005;66:897\u2013902.", "journal-title": "Urology"}, {"key": "14_CR26_14", "doi-asserted-by": "publisher", "first-page": "386", "DOI": "10.1016/j.urology.2005.03.040", "volume": "66", "author": "ME Taplin", "year": "2005", "unstructured": "Taplin ME, George DJ, Halabi S, et al. Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. Urology 2005;66:386\u201391.", "journal-title": "Urology"}, {"key": "14_CR27_14", "doi-asserted-by": "publisher", "first-page": "109", "DOI": "10.1677/erc.1.00876", "volume": "12", "author": "A Berruti", "year": "2005", "unstructured": "Berruti A, Mosca A, Tucci M, et al. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. Endocr Relat Cancer 2005;12:109\u201317.", "journal-title": "Endocr Relat Cancer"}, {"key": "14_CR28_14", "doi-asserted-by": "publisher", "first-page": "203", "DOI": "10.1016/S1535-6108(02)00030-2", "volume": "1", "author": "D Singh", "year": "2002", "unstructured": "Singh D, Febbo PG, Ross K, et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002;1:203\u20139.", "journal-title": "Cancer Cell"}, {"key": "14_CR29_14", "doi-asserted-by": "publisher", "first-page": "1347", "DOI": "10.1016/S0022-5347(05)00640-3", "volume": "175", "author": "A Cabrespine", "year": "2006", "unstructured": "Cabrespine A, Guy L, Gachon F, Cure H, Chollet P, Bay JO. Circulating chromogranin A and hormone refractory prostate cancer chemotherapy. J Urol 2006;175:1347\u201352.", "journal-title": "J Urol"}, {"key": "14_CR30_14", "first-page": "1215", "volume": "14", "author": "M Abdul", "year": "1994", "unstructured": "Abdul M, Anezinis PE, Logothetis CJ, Hoosein NM. Growth inhibition of human prostatic carcinoma cell lines by serotonin antagonists. Anticancer Res 1994;14:1215\u201320.", "journal-title": "Anticancer Res"}, {"key": "14_CR31_14", "doi-asserted-by": "publisher", "first-page": "328", "DOI": "10.1002/pros.10374", "volume": "59", "author": "N Dizeyi", "year": "2004", "unstructured": "Dizeyi N, Bjartell A, Nilsson E, et al. Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines. Prostate 2004;59:328\u201336.", "journal-title": "Prostate"}, {"key": "14_CR32_14", "doi-asserted-by": "publisher", "first-page": "297", "DOI": "10.1677/jme.0.0160297", "volume": "16", "author": "AG Aprikian", "year": "1996", "unstructured": "Aprikian AG, Han K, Chevalier S, Bazinet M, Viallet J. Bombesin specifically induces intracellular calcium mobilization via gastrin-releasing peptide receptors in human prostate cancer cells. J Mol Endocrinol 1996;16:297\u2013306.", "journal-title": "J Mol Endocrinol"}, {"key": "14_CR33_14", "first-page": "1139", "volume": "8", "author": "JC Reubi", "year": "2002", "unstructured": "Reubi JC, Wenger S, Schmuckli-Maurer J, Schaer JC, Gugger M. Bombesin receptor subtypes in human cancers: detection with the universal radioligand (125)I-[D-TYR(6), beta-ALA(11), PHE(13), NLE(14)] bombesin(6\u201314). Clin Cancer Res 2002;8:1139\u201346.", "journal-title": "Clin Cancer Res"}, {"key": "14_CR34_14", "doi-asserted-by": "publisher", "first-page": "183", "DOI": "10.1002/(SICI)1097-0045(19970515)31:3<183::AID-PROS7>3.0.CO;2-M", "volume": "31", "author": "L Seethalakshmi", "year": "1997", "unstructured": "Seethalakshmi L, Mitra SP, Dobner PR, Menon M, Carraway RE. Neurotensin receptor expression in prostate cancer cell line and growth effect of NT at physiological concentrations. Prostate 1997;31:183\u201392.", "journal-title": "Prostate"}, {"issue": "Suppl 2", "key": "14_CR35_14", "doi-asserted-by": "publisher", "first-page": "S27", "DOI": "10.1093/annonc/12.suppl_2.S27", "volume": "12", "author": "P Magni", "year": "2001", "unstructured": "Magni P, Motta M. Expression of neuropeptide Y receptors in human prostate cancer cells. Ann Oncol 2001;12(Suppl 2):S27\u20139.", "journal-title": "Ann Oncol"}, {"key": "14_CR36_14", "doi-asserted-by": "publisher", "first-page": "376", "DOI": "10.1016/S0090-4295(99)80456-7", "volume": "47", "author": "G Wu", "year": "1996", "unstructured": "Wu G, Burzon DT, di Sant\u2019Agnese PA, et al. Calcitonin receptor mRNA expression in the human prostate. Urology 1996;47:376\u201381.", "journal-title": "Urology"}, {"key": "14_CR37_14", "doi-asserted-by": "publisher", "first-page": "563", "DOI": "10.1002/path.993", "volume": "195", "author": "GJ Leenders van", "year": "2001", "unstructured": "van Leenders GJ, Aalders TW, Hulsbergen-van de Kaa CA, Ruiter DJ, Schalken JA. Expression of basal cell keratins in human prostate cancer metastases and cell lines. J Pathol 2001;195:563\u201370.", "journal-title": "J Pathol"}, {"key": "14_CR38_14", "doi-asserted-by": "publisher", "first-page": "2197", "DOI": "10.1038/sj.onc.1207344", "volume": "23", "author": "LF Lee", "year": "2004", "unstructured": "Lee LF, Louie MC, Desai SJ, et al. Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK. Oncogene 2004;23:2197\u2013205.", "journal-title": "Oncogene"}, {"key": "14_CR39_14", "doi-asserted-by": "publisher", "first-page": "1807", "DOI": "10.1016/S0002-9440(10)62490-X", "volume": "166", "author": "J Huang", "year": "2005", "unstructured": "Huang J, Yao JL, Zhang L, et al. Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer. Am J Pathol 2005;166:1807\u201315.", "journal-title": "Am J Pathol"}, {"key": "14_CR40_14", "doi-asserted-by": "publisher", "first-page": "147", "DOI": "10.1016/j.eururo.2004.09.007", "volume": "47", "author": "N Vashchenko", "year": "2005", "unstructured": "Vashchenko N, Abrahamsson PA. Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol 2005;47:147\u201355.", "journal-title": "Eur Urol"}, {"key": "14_CR41_14", "doi-asserted-by": "publisher", "first-page": "671", "DOI": "10.1002/jcb.10771", "volume": "91", "author": "AI Evangelou", "year": "2004", "unstructured": "Evangelou AI, Winter SF, Huss WJ, Bok RA, Greenberg NM. Steroid hormones, polypeptide growth factors, hormone refractory prostate cancer, and the neuroendocrine phenotype. J Cell Biochem 2004;91:671\u201383.", "journal-title": "J Cell Biochem"}, {"key": "14_CR42_14", "doi-asserted-by": "publisher", "first-page": "4599", "DOI": "10.1210/en.2002-220561", "volume": "143", "author": "RM Adam", "year": "2002", "unstructured": "Adam RM, Kim J, Lin J, et al. Heparin-binding epidermal growth factor-like growth factor stimulates androgen-independent prostate tumor growth and antagonizes androgen receptor function. Endocrinology 2002;143:4599\u2013608.", "journal-title": "Endocrinology"}, {"key": "14_CR43_14", "doi-asserted-by": "publisher", "first-page": "3663", "DOI": "10.1158/0008-5472.CAN-06-2616", "volume": "67", "author": "PD Deeble", "year": "2007", "unstructured": "Deeble PD, Cox ME, Frierson HF, Jr., et al. Androgen-independent growth and tumorigenesis of prostate cancer cells are enhanced by the presence of PKA-differentiated neuroendocrine cells. Cancer Res 2007;67:3663\u201372.", "journal-title": "Cancer Res"}, {"key": "14_CR44_14", "doi-asserted-by": "publisher", "first-page": "91", "DOI": "10.1002/pros.20032", "volume": "60", "author": "WJ Huss", "year": "2004", "unstructured": "Huss WJ, Gregory CW, Smith GJ. Neuroendocrine cell differentiation in the CWR22 human prostate cancer xenograft: association with tumor cell proliferation prior to recurrence. Prostate 2004;60:91\u20137.", "journal-title": "Prostate"}, {"key": "14_CR45_14", "doi-asserted-by": "publisher", "first-page": "219", "DOI": "10.1002/pros.10215", "volume": "55", "author": "PJ Kaplan-Lefko", "year": "2003", "unstructured": "Kaplan-Lefko PJ, Chen TM, Ittmann MM, et al. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 2003;55:219\u201337.", "journal-title": "Prostate"}, {"key": "14_CR46_14", "doi-asserted-by": "publisher", "first-page": "7525", "DOI": "10.1158/0008-5472.CAN-07-0668", "volume": "67", "author": "CP Liao", "year": "2007", "unstructured": "Liao CP, Zhong C, Saribekyan G, et al. Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence. Cancer Res 2007;67:7525\u201333.", "journal-title": "Cancer Res"}, {"key": "14_CR47_14", "doi-asserted-by": "publisher", "first-page": "5489", "DOI": "10.1158/0008-5472.CAN-03-3117", "volume": "64", "author": "RJ Jin", "year": "2004", "unstructured": "Jin RJ, Wang Y, Masumori N, et al. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. Cancer Res 2004;64:5489\u201395.", "journal-title": "Cancer Res"}, {"issue": "5", "key": "14_CR48_14", "doi-asserted-by": "publisher", "first-page": "536", "DOI": "10.1002/pros.20369", "volume": "66", "author": "K Uchida", "year": "2006", "unstructured": "Uchida K, Masumori N, Takahashi A, et al. Murine androgen-independent neuroendocrine carcinoma promotes metastasis of human prostate cancer cell line LNCaP. Prostate 2006;66(5):536\u201345.", "journal-title": "Prostate"}, {"key": "14_CR49_14", "doi-asserted-by": "publisher", "first-page": "85", "DOI": "10.1056/NEJMoa003034", "volume": "346", "author": "K Noda", "year": "2002", "unstructured": "Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85\u201391.", "journal-title": "N Engl J Med"}, {"key": "14_CR50_14", "doi-asserted-by": "publisher", "first-page": "1553", "DOI": "10.1002/1097-0142(197911)44:5<1553::AID-CNCR2820440502>3.0.CO;2-W", "volume": "44", "author": "A Yagoda", "year": "1979", "unstructured": "Yagoda A, Watson RC, Natale RB, et al. A critical analysis of response criteria in patients with prostatic cancer treated with cis-diamminedichloride platinum II. Cancer 1979;44:1553\u201362.", "journal-title": "Cancer"}, {"key": "14_CR51_14", "doi-asserted-by": "publisher", "first-page": "203", "DOI": "10.1097/00000421-198304000-00011", "volume": "6", "author": "R Qazi", "year": "1983", "unstructured": "Qazi R, Khandekar J. Phase II study of cisplatin for metastatic prostatic carcinoma. An Eastern Cooperative Oncology Group study. Am J Clin Oncol 1983;6:203\u20135.", "journal-title": "Am J Clin Oncol"}, {"key": "14_CR52_14", "doi-asserted-by": "publisher", "first-page": "1098", "DOI": "10.1002/1097-0142(19930201)71:3+<1098::AID-CNCR2820711432>3.0.CO;2-G", "volume": "71", "author": "A Yagoda", "year": "1993", "unstructured": "Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993;71:1098\u2013109.", "journal-title": "Cancer"}, {"issue": "1", "key": "14_CR53_14", "first-page": "S91", "volume": "8", "author": "DL Trump", "year": "1990", "unstructured": "Trump DL, Marsh JC, Kvols LK, et al. A phase II trial of carboplatin (NSC 241240) in advanced prostate cancer, refractory to hormonal therapy. An Eastern Cooperative Oncology Group pilot study. Invest New Drugs 1990; 8(Suppl 1):S91\u20134.", "journal-title": "Invest New Drugs"}, {"key": "14_CR54_14", "doi-asserted-by": "publisher", "first-page": "2094", "DOI": "10.1016/0959-8049(93)90040-M", "volume": "29A", "author": "L Canobbio", "year": "1993", "unstructured": "Canobbio L, Guarneri D, Miglietta L, et al. Carboplatin in advanced hormone refractory prostatic cancer patients. Eur J Cancer 1993;29A:2094\u20136.", "journal-title": "Eur J Cancer"}, {"key": "14_CR55_14", "first-page": "2825", "volume": "15", "author": "L Miglietta", "year": "1995", "unstructured": "Miglietta L, Cannobbio L, Boccardo F. Assessment of response to carboplatin in patients with hormone-refractory prostate cancer: a critical analysis of drug activity. Anticancer Res 1995;15:2825\u20138.", "journal-title": "Anticancer Res"}, {"key": "14_CR56_14", "doi-asserted-by": "publisher", "first-page": "462", "DOI": "10.1007/s005200050195", "volume": "6", "author": "WF Jungi", "year": "1998", "unstructured": "Jungi WF, Bernhard J, Hurny C, et al. Effect of carboplatin on response and palliation in hormone-refractory prostate cancer. Swiss Group for Clinical Cancer Research (SAKK). Support Care Cancer 1998;6:462\u20138.", "journal-title": "Support Care Cancer"}, {"key": "14_CR57_14", "author": "B Castagneto", "year": "2006", "unstructured": "Castagneto B, Ferraris V, Perachino M, et al. Weekly administration of standardized low-dose carboplatin (CBDCA) in the treatment of advanced hormone refractory prostate cancer (CRPC): a phase II study. Proceedings GH Cancer Symposium 2006; abstract 243.", "volume-title": "Weekly administration of standardized low-dose carboplatin (CBDCA) in the treatment of advanced hormone refractory prostate cancer (CRPC): a phase II study"}, {"key": "14_CR58_14", "doi-asserted-by": "publisher", "first-page": "201", "DOI": "10.1002/1097-0142(19820715)50:2<201::AID-CNCR2820500205>3.0.CO;2-7", "volume": "50", "author": "DL Citrin", "year": "1982", "unstructured": "Citrin DL, Hogan TF. A phase II evaluation of adriamycin and cis-platinum in hormone resistant prostate cancer. Cancer 1982;50:201\u20136.", "journal-title": "Cancer"}, {"key": "14_CR59_14", "first-page": "235", "volume": "243B", "author": "JP Droz", "year": "1987", "unstructured": "Droz JP, Fargeot P, Laplaige P, et al. Phase II trial of the association of doxorubicin, 5 FU and cis platinum in hormonally unresponsive metastatic carcinoma of the prostate. Prog Clin Biol Res 1987;243B:235\u201342.", "journal-title": "Prog Clin Biol Res"}, {"key": "14_CR60_14", "first-page": "1437", "volume": "33", "author": "WC Mertens", "year": "1992", "unstructured": "Mertens WC, Porter AT, Reid RH, et al. Strontium-89 and low-dose infusion cisplatin for patients with hormone refractory prostate carcinoma metastatic to bone: a preliminary report. J Nucl Med 1992;33:1437\u201343.", "journal-title": "J Nucl Med"}, {"key": "14_CR61_14", "doi-asserted-by": "publisher", "first-page": "225", "DOI": "10.1007/BF00686552", "volume": "35", "author": "S Naito", "year": "1995", "unstructured": "Naito S, Ueda T, Kotoh S, et al. Treatment of advanced hormone-refractory prostate carcinoma with a combination of etoposide, pirarubicin and cisplatin. Cancer Chemother Pharmacol 1995;35:225\u20139.", "journal-title": "Cancer Chemother Pharmacol"}, {"key": "14_CR62_14", "doi-asserted-by": "publisher", "first-page": "477", "DOI": "10.1016/S0959-8049(05)80080-2", "volume": "28", "author": "CK Osborne", "year": "1992", "unstructured": "Osborne CK, Blumenstein BA, Crawford ED, et al. Phase II study of platinum and mitoxantrone in metastatic prostate cancer: a Southwest Oncology Group Study. Eur J Cancer 1992;28:477\u20138.", "journal-title": "Eur J Cancer"}, {"key": "14_CR63_14", "doi-asserted-by": "publisher", "first-page": "668", "DOI": "10.1080/028418602321028292", "volume": "41", "author": "G Steineck", "year": "2002", "unstructured": "Steineck G, Reuter V, Kelly WK, et al. Cytotoxic treatment of aggressive prostate tumors with or without neuroendocrine elements. Acta Oncol 2002;41:668\u201374.", "journal-title": "Acta Oncol"}, {"key": "14_CR64_14", "doi-asserted-by": "publisher", "first-page": "266", "DOI": "10.1002/cncr.21982", "volume": "107", "author": "TW Flaig", "year": "2006", "unstructured": "Flaig TW, Barqawi A, Miller G, et al. A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone- refractory prostate cancer. Cancer 2006;107:266\u201374.", "journal-title": "Cancer"}, {"issue": "9253", "key": "14_CR65_14", "doi-asserted-by": "publisher", "first-page": "336", "DOI": "10.1016/S0140-6736(00)03639-4", "volume": "357", "author": "SM Tu", "year": "2001", "unstructured": "Tu SM, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 2001;357(9253):336\u201341.", "journal-title": "Lancet"}, {"key": "14_CR66_14", "doi-asserted-by": "publisher", "first-page": "131", "DOI": "10.3816/CGC.2006.n.029", "volume": "5", "author": "W Berry", "year": "2006", "unstructured": "Berry W, Friedland D, Fleagle J, et al. A phase II study of weekly paclitaxel/estramustine/carboplatin in hormone-refractory prostate cancer. Clin Genitourin Cancer 2006;5:131\u20137.", "journal-title": "Clin Genitourin Cancer"}, {"key": "14_CR67_14", "doi-asserted-by": "crossref", "first-page": "44", "DOI": "10.1200/JCO.2001.19.1.44", "volume": "19", "author": "WK Kelly", "year": "2001", "unstructured": "Kelly WK, Curley T, Slovin S, et al. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol 2001;19:44\u201353.", "journal-title": "J Clin Oncol"}, {"key": "14_CR68_14", "doi-asserted-by": "publisher", "first-page": "2444", "DOI": "10.1016/S0022-5347(05)64164-X", "volume": "168", "author": "S Urakami", "year": "2002", "unstructured": "Urakami S, Igawa M, Kikuno N, et al. Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer. J Urol 2002;168: 2444\u201350.", "journal-title": "J Urol"}, {"key": "14_CR69_14", "doi-asserted-by": "publisher", "first-page": "1842", "DOI": "10.1002/cncr.11754", "volume": "98", "author": "DB Solit", "year": "2003", "unstructured": "Solit DB, Morris M, Slovin S, et al. Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma. Cancer 2003;98:1842\u20138.", "journal-title": "Cancer"}, {"issue": "5", "key": "14_CR70_14", "doi-asserted-by": "publisher", "first-page": "1252", "DOI": "10.1016/j.eururo.2006.12.030", "volume": "51", "author": "N Kikuno", "year": "2008", "unstructured": "Kikuno N, Urakami S, Nakamura S, et al. Phase-II study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer. Eur Urol 2008;51(5):1252\u20138.", "journal-title": "Eur Urol"}, {"key": "14_CR71_14", "doi-asserted-by": "publisher", "first-page": "2592", "DOI": "10.1002/cncr.11829", "volume": "98", "author": "WK Oh", "year": "2003", "unstructured": "Oh WK, Halabi S, Kelly WK, et al. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. Cancer 2003;98:2592\u20138.", "journal-title": "Cancer"}, {"key": "14_CR72_14", "first-page": "284", "volume": "11", "author": "WK Oh", "year": "2005", "unstructured": "Oh WK, Hagmann E, Manola J, et al. A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer. Clin Cancer Res 2005;11:284\u20139.", "journal-title": "Clin Cancer Res"}, {"key": "14_CR73_14", "first-page": "263", "volume": "1", "author": "MP Hay", "year": "2000", "unstructured": "Hay MP. ZD-0473 AstraZeneca. Curr Opin Investig Drugs 2000;1:263\u20136.", "journal-title": "Curr Opin Investig Drugs"}, {"key": "14_CR74_14", "doi-asserted-by": "publisher", "first-page": "119", "DOI": "10.1517/13543784.10.1.119", "volume": "10", "author": "MJ McKeage", "year": "2001", "unstructured": "McKeage MJ. Lobaplatin: a new antitumour platinum drug. Expert Opin Investig Drugs 2001;10:119\u201328.", "journal-title": "Expert Opin Investig Drugs"}, {"issue": "3", "key": "14_CR75_14", "doi-asserted-by": "publisher", "first-page": "521", "DOI": "10.1002/cncr.23195", "volume": "112", "author": "RW Ross", "year": "2008", "unstructured": "Ross RW, Beer TM, Jacobus S, Bubley GJ, Taplin ME, Ryan CW, Huang J, Oh WK. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer 2008;112(3):521\u20136.", "journal-title": "Cancer"}, {"key": "14_CR76_14", "first-page": "18S", "volume": "25", "author": "M Nakabayashi", "year": "2007", "unstructured": "Nakabayashi M, Sartor O, Jacobus S, et al. Response to docetaxel (D)/carboplatin (C)-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer (CRPC). J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007.", "journal-title": "J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I"}, {"key": "14_CR78_14", "doi-asserted-by": "publisher", "first-page": "5431", "DOI": "10.1200/JCO.2008.20.1228", "volume": "27", "author": "CN Sternberg", "year": "2009", "unstructured": "Sternberg CN, Petrylak DP, Sartor O, et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 2009;27:5431\u20138.", "journal-title": "J Clin Oncol"}], "container-title": ["Drug Management of Prostate Cancer"], "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/978-1-60327-829-4_14", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 13]], "date-time": "2019-05-13T20:22:20Z", "timestamp": 1557778940000}, "score": 21.611076, "issued": {"date-parts": [[2010]]}, "ISBN": ["9781603278317", "9781603278294"], "references-count": 73, "URL": "http://dx.doi.org/10.1007/978-1-60327-829-4_14", "relation": {"cites": []}}, {"institution": {"name": "ISRCTN", "place": ["London, UK"], "acronym": ["-"]}, "indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T17:03:19Z", "timestamp": 1574528599784}, "reference-count": 0, "publisher": "Springer Science and Business Media LLC", "content-domain": {"domain": ["www.isrctn.com"], "crossmark-restriction": true}, "DOI": "10.1186/isrctn98093105", "type": "dataset", "created": {"date-parts": [[2013, 1, 21]], "date-time": "2013-01-21T15:00:19Z", "timestamp": 1358780419000}, "update-policy": "http://dx.doi.org/10.1186/isrctn_crossmark_policy", "source": "Crossref", "is-referenced-by-count": 1, "title": ["Use of analgesic for children having dental treatment under local anaesthesia"], "prefix": "10.1186", "author": [{"given": "Paul", "family": "Ashley", "sequence": "first", "affiliation": []}], "member": "297", "content-created": {"date-parts": [[2013, 1, 21]]}, "container-title": ["http://isrctn.org/>"], "deposited": {"date-parts": [[2015, 6, 12]], "date-time": "2015-06-12T13:56:14Z", "timestamp": 1434117374000}, "score": 21.410229, "issued": {"date-parts": [[2013, 1, 21]]}, "references-count": 0, "URL": "http://dx.doi.org/10.1186/isrctn98093105"}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T18:49:08Z", "timestamp": 1574448548385}, "reference-count": 16, "publisher": "Wiley", "issue": "5", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 1310, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2012, 9]]}, "DOI": "10.1111/j.1464-410x.2011.10875.x", "type": "journal-article", "created": {"date-parts": [[2012, 1, 30]], "date-time": "2012-01-30T18:33:13Z", "timestamp": 1327948393000}, "page": "651-657", "source": "Crossref", "is-referenced-by-count": 18, "title": ["Effect of treatment with 5-\u03b1 reductase inhibitors on progression in monitored men with favourable-risk prostate cancer"], "prefix": "10.1111", "volume": "110", "author": [{"given": "Ashley E.", "family": "Ross", "sequence": "first", "affiliation": []}, {"given": "Zhaoyong", "family": "Feng", "sequence": "additional", "affiliation": []}, {"given": "Phillip M.", "family": "Pierorazio", "sequence": "additional", "affiliation": []}, {"given": "Patricia", "family": "Landis", "sequence": "additional", "affiliation": []}, {"given": "Patrick C.", "family": "Walsh", "sequence": "additional", "affiliation": []}, {"given": "H. Ballentine", "family": "Carter", "sequence": "additional", "affiliation": []}, {"given": "Bruce J.", "family": "Trock", "sequence": "additional", "affiliation": []}, {"given": "Edward M.", "family": "Schaeffer", "sequence": "additional", "affiliation": []}], "member": "311", "published-online": {"date-parts": [[2012, 1, 30]]}, "reference": [{"key": "10.1111/j.1464-410X.2011.10875.x-BIB1|cit1", "doi-asserted-by": "crossref", "first-page": "868", "DOI": "10.1093/jnci/95.12.868", "article-title": "Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer", "volume": "95", "author": "Draisma", "year": "2003", "journal-title": "J Natl Cancer Inst"}, {"key": "10.1111/j.1464-410X.2011.10875.x-BIB2|cit2", "doi-asserted-by": "crossref", "first-page": "S14", "DOI": "10.1016/j.juro.2007.03.135", "article-title": "Contemporary trends in low risk prostate cancer: risk assessment and treatment", "volume": "178", "author": "Cooperberg", "year": "2007", "journal-title": "J Urol"}, {"key": "10.1111/j.1464-410X.2011.10875.x-BIB3|cit3", "doi-asserted-by": "crossref", "first-page": "2810", "DOI": "10.1200/JCO.2009.25.7311", "article-title": "Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program", "volume": "28", "author": "Ross", "year": "2010", "journal-title": "J Clin Oncol"}, {"key": "10.1111/j.1464-410X.2011.10875.x-BIB4|cit4", "doi-asserted-by": "crossref", "first-page": "1656", "DOI": "10.1016/j.juro.2010.12.042", "article-title": "The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer", "volume": "185", "author": "Whitson", "year": "2011", "journal-title": "J Urol"}, {"key": "10.1111/j.1464-410X.2011.10875.x-BIB5|cit5", "doi-asserted-by": "crossref", "first-page": "1192", "DOI": "10.1056/NEJMoa0908127", "article-title": "Effect of dutasteride on the risk of prostate cancer", "volume": "362", "author": "Andriole", "year": "2010", "journal-title": "N Engl J Med"}, {"key": "10.1111/j.1464-410X.2011.10875.x-BIB6|cit6", "doi-asserted-by": "crossref", "first-page": "215", "DOI": "10.1056/NEJMoa030660", "article-title": "The influence of finasteride on the development of prostate cancer", "volume": "349", "author": "Thompson", "year": "2003", "journal-title": "N Engl J Med"}, {"key": "10.1111/j.1464-410X.2011.10875.x-BIB7|cit7", "doi-asserted-by": "crossref", "first-page": "763", "DOI": "10.1016/j.cct.2007.05.006", "article-title": "Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial", "volume": "28", "author": "Fleshner", "year": "2007", "journal-title": "Contemp Clin Trials"}, {"key": "10.1111/j.1464-410X.2011.10875.x-BIB8|cit8", "doi-asserted-by": "crossref", "first-page": "509", "DOI": "10.1016/j.eururo.2010.12.018", "article-title": "Impact of 5alpha-reductase inhibitors on men followed by active surveillance for prostate cancer", "volume": "59", "author": "Finelli", "year": "2011", "journal-title": "Eur Urol"}, {"key": "10.1111/j.1464-410X.2011.10875.x-BIB9|cit9", "doi-asserted-by": "crossref", "first-page": "2185", "DOI": "10.1200/JCO.2010.32.8112", "article-title": "Active surveillance program for prostate cancer: an update of the johns hopkins experience", "volume": "29", "author": "Tosoian", "year": "2011", "journal-title": "J Clin Oncol"}, {"key": "10.1111/j.1464-410X.2011.10875.x-BIB10|cit10", "doi-asserted-by": "crossref", "first-page": "1779", "DOI": "10.1016/j.juro.2010.01.001", "article-title": "Risk stratification of men choosing surveillance for low risk prostate cancer", "volume": "183", "author": "Tseng", "year": "2010", "journal-title": "J Urol"}, {"key": "10.1111/j.1464-410X.2011.10875.x-BIB11|cit11", "doi-asserted-by": "crossref", "first-page": "2387", "DOI": "10.1056/NEJMoa030656", "article-title": "The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia", "volume": "349", "author": "McConnell", "year": "2003", "journal-title": "N Engl J Med"}, {"key": "10.1111/j.1464-410X.2011.10875.x-BIB12|cit12", "doi-asserted-by": "crossref", "first-page": "709", "DOI": "10.1016/j.urology.2004.01.001", "article-title": "Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia", "volume": "63", "author": "Roehrborn", "year": "2004", "journal-title": "Urology"}, {"key": "10.1111/j.1464-410X.2011.10875.x-BIB13|cit13", "unstructured": "FDA. Oncologic Drugs Advisory Comittee Metting regarding AVODART (dutasteride) NDA 21319/S0024 2010 http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommitte/UCM234934"}, {"key": "10.1111/j.1464-410X.2011.10875.x-BIB14|cit14", "unstructured": "FDA. Oncologic Drugs Advisory Comittee Metting regarding PROSCAR (finasteride) NDA 20180/S034 2010 http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommitte/UCM234934"}, {"key": "10.1111/j.1464-410X.2011.10875.x-BIB15|cit15", "doi-asserted-by": "crossref", "first-page": "183", "DOI": "10.1016/j.eururo.2010.09.035", "article-title": "Prostate cancer detection and dutasteride: utility and limitations of prostate-specific antigen in men with previous negative biopsies", "volume": "59", "author": "van Leeuwen", "year": "2011", "journal-title": "Eur Urol"}, {"key": "10.1111/j.1464-410X.2011.10875.x-BIB16|cit16", "author": "Fleshner", "year": "2011", "article-title": "Dutasteride reduces prostate cancer progression and cancer diagnosis on re-biopsy in the REDEEM active surveillance study", "journal-title": "SUO"}], "container-title": ["BJU International"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1464-410X.2011.10875.x", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2017, 6, 20]], "date-time": "2017-06-20T13:30:47Z", "timestamp": 1497965447000}, "score": 21.314056, "subtitle": ["5-ARI USE IN FAVOURABLE RISK PROSTATE CANCER"], "issued": {"date-parts": [[2012, 1, 30]]}, "references-count": 16, "journal-issue": {"published-print": {"date-parts": [[2012, 9]]}, "issue": "5"}, "URL": "http://dx.doi.org/10.1111/j.1464-410x.2011.10875.x", "relation": {"cites": []}, "ISSN": ["1464-4096"], "issn-type": [{"value": "1464-4096", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T14:09:16Z", "timestamp": 1575209356820}, "reference-count": 0, "publisher": "American College of Physicians", "issue": "8_Part_1", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Ann Intern Med"], "published-print": {"date-parts": [[1997, 10, 15]]}, "DOI": "10.7326/0003-4819-127-8_part_1-199710150-00029", "type": "journal-article", "created": {"date-parts": [[2013, 4, 12]], "date-time": "2013-04-12T17:22:13Z", "timestamp": 1365787333000}, "page": "656", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Early Detection of Prostate Cancer"], "prefix": "10.7326", "volume": "127", "author": [{"given": "Thomas", "family": "Ashley", "sequence": "first", "affiliation": []}], "member": "4285", "container-title": ["Annals of Internal Medicine"], "language": "en", "deposited": {"date-parts": [[2013, 4, 12]], "date-time": "2013-04-12T17:22:13Z", "timestamp": 1365787333000}, "score": 21.26107, "issued": {"date-parts": [[1997, 10, 15]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[1997, 10, 15]]}, "issue": "8_Part_1"}, "URL": "http://dx.doi.org/10.7326/0003-4819-127-8_part_1-199710150-00029", "ISSN": ["0003-4819"], "issn-type": [{"value": "0003-4819", "type": "print"}], "subject": ["Internal Medicine", "General Medicine"]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T05:37:32Z", "timestamp": 1574746652849}, "reference-count": 212, "publisher": "Elsevier BV", "issue": "1", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2016, 2, 1]], "date-time": "2016-02-01T00:00:00Z", "timestamp": 1454284800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": ["clinicalkey.jp", "clinicalkey.com", "urologic.theclinics.com", "clinicalkey.es", "theclinics.com", "clinicalkey.com.au", "clinicalkey.fr", "elsevier.com", "sciencedirect.com"], "crossmark-restriction": true}, "short-container-title": ["Urologic Clinics of North America"], "published-print": {"date-parts": [[2016, 2]]}, "DOI": "10.1016/j.ucl.2015.08.003", "type": "journal-article", "created": {"date-parts": [[2015, 11, 27]], "date-time": "2015-11-27T15:17:09Z", "timestamp": 1448637429000}, "page": "17-38", "update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy", "source": "Crossref", "is-referenced-by-count": 22, "title": ["Urinary Biomarkers for Prostate Cancer"], "prefix": "10.1016", "volume": "43", "author": [{"given": "Jeffrey J.", "family": "Tosoian", "sequence": "first", "affiliation": []}, {"given": "Ashley E.", "family": "Ross", "sequence": "additional", "affiliation": []}, {"given": "Lori J.", "family": "Sokoll", "sequence": "additional", "affiliation": []}, {"given": "Alan W.", "family": "Partin", "sequence": "additional", "affiliation": []}, {"given": "Christian P.", "family": "Pavlovich", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Urologic Clinics of North America"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0094014315000853?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0094014315000853?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 9, 2]], "date-time": "2019-09-02T00:48:45Z", "timestamp": 1567385325000}, "score": 21.171146, "issued": {"date-parts": [[2016, 2]]}, "references-count": 212, "journal-issue": {"published-print": {"date-parts": [[2016, 2]]}, "issue": "1"}, "alternative-id": ["S0094014315000853"], "URL": "http://dx.doi.org/10.1016/j.ucl.2015.08.003", "ISSN": ["0094-0143"], "issn-type": [{"value": "0094-0143", "type": "print"}], "assertion": [{"value": "Elsevier", "name": "publisher", "label": "This article is maintained by"}, {"value": "Urinary Biomarkers for Prostate Cancer", "name": "articletitle", "label": "Article Title"}, {"value": "Urologic Clinics of North America", "name": "journaltitle", "label": "Journal Title"}, {"value": "https://doi.org/10.1016/j.ucl.2015.08.003", "name": "articlelink", "label": "CrossRef DOI link to publisher maintained version"}, {"value": "article", "name": "content_type", "label": "Content Type"}, {"value": "Copyright \u00a9 2016 Elsevier Inc. All rights reserved.", "name": "copyright", "label": "Copyright"}]}, {"institution": {"name": "Florida International University", "place": ["-"], "acronym": ["FIU"]}, "indexed": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T12:32:34Z", "timestamp": 1574857954636}, "reference-count": 0, "publisher": "Florida International University", "content-domain": {"domain": [], "crossmark-restriction": false}, "DOI": "10.25148/etd.fi14032371", "type": "dissertation", "created": {"date-parts": [[2017, 11, 13]], "date-time": "2017-11-13T19:42:27Z", "timestamp": 1510602147000}, "approved": {"date-parts": [[2007, 6, 19]]}, "source": "Crossref", "is-referenced-by-count": 0, "title": ["Treatment attrition among racial/ethnic minority adolescents participating in a brief motivational intervention for substance use problems : the influence of individual, social, cultural, and treatment factors"], "prefix": "10.25148", "author": [{"given": "Ashley", "family": "Austin", "sequence": "first", "affiliation": []}], "member": "10777", "deposited": {"date-parts": [[2017, 11, 13]], "date-time": "2017-11-13T19:42:47Z", "timestamp": 1510602167000}, "score": 21.141665, "degree": ["Doctor of Philosophy (PhD)\n \nSocial Welfare"], "issued": {"date-parts": [[null]]}, "references-count": 0, "URL": "http://dx.doi.org/10.25148/etd.fi14032371"}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T23:12:46Z", "timestamp": 1574550766576}, "reference-count": 38, "publisher": "SAGE Publications", "issue": "6", "license": [{"URL": "http://journals.sagepub.com/page/policies/text-and-data-mining-license", "start": {"date-parts": [[2010, 12, 1]], "date-time": "2010-12-01T00:00:00Z", "timestamp": 1291161600000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Technol Cancer Res Treat"], "published-print": {"date-parts": [[2010, 12]]}, "DOI": "10.1177/153303461000900605", "type": "journal-article", "created": {"date-parts": [[2014, 10, 3]], "date-time": "2014-10-03T18:55:00Z", "timestamp": 1412362500000}, "page": "575-582", "source": "Crossref", "is-referenced-by-count": 40, "title": ["Stereotactic Body Radiotherapy as Boost for Organ-confined Prostate Cancer"], "prefix": "10.1177", "volume": "9", "author": [{"given": "Alan J.", "family": "Katz", "sequence": "first", "affiliation": [{"name": "Winthrop University Hospital, Mineola, NY"}]}, {"given": "Michael", "family": "Santoro", "sequence": "additional", "affiliation": [{"name": "Winthrop University Hospital, Mineola, NY"}]}, {"given": "Richard", "family": "Ashley", "sequence": "additional", "affiliation": [{"name": "Winthrop University Hospital, Mineola, NY"}]}, {"given": "Ferdinand", "family": "Diblasio", "sequence": "additional", "affiliation": [{"name": "Winthrop University Hospital, Mineola, NY"}]}, {"given": "Matthew", "family": "Witten", "sequence": "additional", "affiliation": [{"name": "Winthrop University Hospital, Mineola, NY"}]}], "member": "179", "published-online": {"date-parts": [[2010, 12]]}, "reference": [{"key": "bibr2-153303461000900605", "DOI": "10.1016/0360-3016(86)90059-3", "doi-asserted-by": "publisher"}, {"key": "bibr3-153303461000900605", "DOI": "10.1016/0360-3016(87)90063-0", "doi-asserted-by": "publisher"}, {"key": "bibr4-153303461000900605", "DOI": "10.1002/1097-0142(19871001)60:7<1489::AID-CNCR2820600715>3.0.CO;2-9", "doi-asserted-by": "publisher"}, {"key": "bibr5-153303461000900605", "DOI": "10.1097/01.ju.0000100980.13364.a6", "doi-asserted-by": "publisher"}, {"key": "bibr6-153303461000900605", "DOI": "10.1016/S0360-3016(02)02829-8", "doi-asserted-by": "publisher"}, {"key": "bibr7-153303461000900605", "DOI": "10.1016/S0360-3016(03)00784-3", "doi-asserted-by": "publisher"}, {"key": "bibr8-153303461000900605", "DOI": "10.1016/j.juro.2006.06.002", "doi-asserted-by": "publisher"}, {"key": "bibr9-153303461000900605", "DOI": "10.1016/j.ijrobp.2005.07.981", "doi-asserted-by": "publisher"}, {"key": "bibr10-153303461000900605", "DOI": "10.1016/j.ijrobp.2008.04.038", "doi-asserted-by": "publisher"}, {"key": "bibr11-153303461000900605", "DOI": "10.1016/j.ijrobp.2006.07.1382", "doi-asserted-by": "publisher"}, {"key": "bibr12-153303461000900605", "DOI": "10.1016/j.ijrobp.2004.08.014", "doi-asserted-by": "publisher"}, {"key": "bibr13-153303461000900605", "DOI": "10.1016/j.ijrobp.2003.08.003", "doi-asserted-by": "publisher"}, {"key": "bibr14-153303461000900605", "DOI": "10.1016/j.ijrobp.2003.11.035", "doi-asserted-by": "publisher"}, {"key": "bibr15-153303461000900605", "DOI": "10.1016/S0360-3016(02)02733-5", "doi-asserted-by": "publisher"}, {"key": "bibr16-153303461000900605", "DOI": "10.1016/j.juro.2006.08.109", "doi-asserted-by": "publisher"}, {"key": "bibr17-153303461000900605", "DOI": "10.1177/153303460600500410", "doi-asserted-by": "publisher"}, {"key": "bibr18-153303461000900605", "DOI": "10.1016/S0090-4295(00)00858-X", "doi-asserted-by": "publisher"}, {"key": "bibr19-153303461000900605", "author": "National Institutes of Health", "year": "1998", "volume-title": "Common toxicity criteria"}, {"key": "bibr20-153303461000900605", "DOI": "10.1016/j.ijrobp.2006.04.029", "doi-asserted-by": "publisher"}, {"key": "bibr21-153303461000900605", "DOI": "10.1016/j.ijrobp.2008.12.067", "doi-asserted-by": "publisher"}, {"key": "bibr22-153303461000900605", "DOI": "10.7150/ijms.5.113", "doi-asserted-by": "publisher"}, {"key": "bibr23-153303461000900605", "DOI": "10.1016/j.ijrobp.2006.04.002", "doi-asserted-by": "publisher"}, {"key": "bibr24-153303461000900605", "DOI": "10.1016/j.radonc.2006.05.013", "doi-asserted-by": "publisher"}, {"key": "bibr25-153303461000900605", "DOI": "10.1016/j.ijrobp.2008.11.023", "doi-asserted-by": "publisher"}, {"key": "bibr26-153303461000900605", "DOI": "10.1080/02841860601156140", "doi-asserted-by": "publisher"}, {"key": "bibr27-153303461000900605", "author": "Soumarova R.", "volume": "53", "first-page": "410", "year": "2006", "journal-title": "Neoplasma"}, {"key": "bibr28-153303461000900605", "author": "Ishiyama H.", "volume": "75", "first-page": "23", "year": "2009", "journal-title": "Int J Radiat Oncol Biol Phys", "DOI": "10.1016/j.ijrobp.2008.11.006", "doi-asserted-by": "crossref"}, {"key": "bibr29-153303461000900605", "DOI": "10.1001/jama.294.10.1233", "doi-asserted-by": "publisher"}, {"key": "bibr30-153303461000900605", "DOI": "10.1016/j.ijrobp.2007.05.057", "doi-asserted-by": "publisher"}, {"key": "bibr31-153303461000900605", "DOI": "10.1016/j.radonc.2007.05.019", "doi-asserted-by": "publisher"}, {"key": "bibr32-153303461000900605", "DOI": "10.1016/j.ijrobp.2009.07.717", "doi-asserted-by": "publisher"}, {"key": "bibr33-153303461000900605", "DOI": "10.1056/NEJMoa074311", "doi-asserted-by": "publisher"}, {"key": "bibr34-153303461000900605", "DOI": "10.1080/01485010490448444", "doi-asserted-by": "publisher"}, {"key": "bibr35-153303461000900605", "author": "Vicini F. A.", "volume": "6", "first-page": "135", "year": "2000", "journal-title": "Tech Urol"}, {"key": "bibr36-153303461000900605", "DOI": "10.1016/j.urology.2007.03.008", "doi-asserted-by": "publisher"}, {"key": "bibr37-153303461000900605", "DOI": "10.1016/j.ijrobp.2008.02.055", "doi-asserted-by": "publisher"}, {"key": "bibr38-153303461000900605", "DOI": "10.1016/j.ijrobp.2007.11.067", "doi-asserted-by": "publisher"}, {"key": "bibr39-153303461000900605", "DOI": "10.1016/j.ijrobp.2008.04.051", "doi-asserted-by": "publisher"}], "container-title": ["Technology in Cancer Research & Treatment"], "language": "en", "link": [{"URL": "http://journals.sagepub.com/doi/pdf/10.1177/153303461000900605", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://journals.sagepub.com/doi/pdf/10.1177/153303461000900605", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 12, 19]], "date-time": "2017-12-19T20:18:46Z", "timestamp": 1513714726000}, "score": 21.009708, "issued": {"date-parts": [[2010, 12]]}, "references-count": 38, "journal-issue": {"published-online": {"date-parts": [[2010, 12]]}, "published-print": {"date-parts": [[2010, 12]]}, "issue": "6"}, "alternative-id": ["10.1177/153303461000900605"], "URL": "http://dx.doi.org/10.1177/153303461000900605", "relation": {"cites": []}, "ISSN": ["1533-0346", "1533-0338"], "issn-type": [{"value": "1533-0346", "type": "print"}, {"value": "1533-0338", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T21:46:26Z", "timestamp": 1574891186329}, "reference-count": 0, "publisher": "BMJ Publishing Group Ltd", "content-domain": {"domain": ["bmj.com"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2018, 6]]}, "DOI": "10.1136/bmjebm-2018-111024.54", "type": "proceedings-article", "created": {"date-parts": [[2018, 10, 23]], "date-time": "2018-10-23T00:23:23Z", "timestamp": 1540254203000}, "update-policy": "http://dx.doi.org/10.1136/crossmarkpolicy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["54\u2005Does personalised genetic-risk information impact decision-making for colorectal cancer screening? a systematic literature review"], "prefix": "10.1136", "author": [{"given": "Ashley", "family": "Duenas", "sequence": "first", "affiliation": []}], "member": "239", "event": {"name": "Evidence Live Abstracts, June 2018, Oxford, UK"}, "container-title": ["Poster Sessions"], "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1136/bmjebm-2018-111024.54", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2018, 10, 23]], "date-time": "2018-10-23T00:23:39Z", "timestamp": 1540254219000}, "score": 20.93826, "issued": {"date-parts": [[2018, 6]]}, "references-count": 0, "alternative-id": ["10.1136/bmjebm-2018-111024.54"], "URL": "http://dx.doi.org/10.1136/bmjebm-2018-111024.54"}, {"indexed": {"date-parts": [[2019, 12, 2]], "date-time": "2019-12-02T06:28:34Z", "timestamp": 1575268114491}, "reference-count": 75, "publisher": "Hindawi Limited", "license": [{"URL": "http://creativecommons.org/licenses/by/3.0/", "start": {"date-parts": [[2013, 1, 1]], "date-time": "2013-01-01T00:00:00Z", "timestamp": 1356998400000}, "delay-in-days": 0, "content-version": "unspecified"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Prostate Cancer"], "published-print": {"date-parts": [[2013]]}, "abstract": "<jats:p>Majority of patients with metastatic castrate resistant prostate cancer (mCRPC) develop bone metastases which results in significant morbidity and mortality as a result of skeletal-related events (SREs). Several bone-targeted agents are either in clinical use or in development for prevention of SREs. Bisphosphonates were the first class of drugs investigated for prevention of SREs and zoledronic acid is the only bisphosphonate that is FDA-approved for this indication. Another bone-targeted agent is denosumab which is a fully humanized monoclonal antibody that binds to the RANK-L thereby inhibiting RANK-L mediated bone resorption. While several radiopharmaceuticals were approved for pain palliation in mCRPC including strontium and samarium, alpharadin is the first radiopharmaceutical to show significant overall survival benefit. Contemporary therapeutic options including enzalutamide and abiraterone have effects on pain palliation and SREs as well. Other novel bone-targeted agents are currently in development, including the receptor tyrosine kinase inhibitors cabozantinib and dasatinib. Emerging therapeutics in mCRPC has resulted in great strides in preventing one of the most significant sources of complications of bone metastases.</jats:p>", "DOI": "10.1155/2013/210686", "type": "journal-article", "created": {"date-parts": [[2013, 8, 28]], "date-time": "2013-08-28T21:06:48Z", "timestamp": 1377724008000}, "page": "1-10", "source": "Crossref", "is-referenced-by-count": 22, "title": ["Bone-Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer: Evolving Paradigms"], "prefix": "10.1155", "volume": "2013", "author": [{"ORCID": "http://orcid.org/0000-0002-2321-9617", "authenticated-orcid": true, "given": "Joelle", "family": "El-Amm", "sequence": "first", "affiliation": [{"name": "Division of Hematology/Oncology, Department of Medicine, George Washington University Medical Center, 2150 Pennsylvania Avenue NW, Washington, DC 20037, USA"}]}, {"given": "Ashley", "family": "Freeman", "sequence": "additional", "affiliation": [{"name": "Department of Medicine, George Washington University Medical Center, Washington, DC 20037, USA"}]}, {"ORCID": "http://orcid.org/0000-0002-1147-7328", "authenticated-orcid": true, "given": "Nihar", "family": "Patel", "sequence": "additional", "affiliation": [{"name": "Division of Hematology/Oncology, Department of Medicine, George Washington University Medical Center, 2150 Pennsylvania Avenue NW, Washington, DC 20037, USA"}]}, {"given": "Jeanny B.", "family": "Aragon-Ching", "sequence": "additional", "affiliation": [{"name": "Division of Hematology/Oncology, Department of Medicine, George Washington University Medical Center, 2150 Pennsylvania Avenue NW, Washington, DC 20037, USA"}]}], "member": "98", "reference": [{"key": "1", "DOI": "10.3322/caac.20138", "doi-asserted-by": "publisher"}, {"key": "2", "volume": "31", "issue": "5", "first-page": "578", "year": "2000", "journal-title": "Human Pathology", "DOI": "10.1053/hp.2000.6698", "doi-asserted-by": "crossref"}, {"key": "3", "DOI": "10.1007/s00520-008-0418-0", "doi-asserted-by": "publisher"}, {"key": "4", "volume": "17", "issue": "3", "first-page": "948", "year": "1999", "journal-title": "Journal of Clinical Oncology", "DOI": "10.1200/JCO.1999.17.3.948", "doi-asserted-by": "crossref"}, {"key": "5", "volume": "94", "issue": "19", "first-page": "1458", "year": "2002", "journal-title": "Journal of the National Cancer Institute", "DOI": "10.1093/jnci/94.19.1458", "doi-asserted-by": "crossref"}, {"key": "6", "volume": "96", "issue": "11", "first-page": "879", "year": "2004", "journal-title": "Journal of the National Cancer Institute", "DOI": "10.1093/jnci/djh141", "doi-asserted-by": "crossref"}, {"key": "7", "DOI": "10.1002/jcb.10662", "doi-asserted-by": "publisher"}, {"key": "8", "DOI": "10.1056/NEJMoa040720", "doi-asserted-by": "publisher"}, {"key": "9", "DOI": "10.1056/NEJMoa041318", "doi-asserted-by": "publisher"}, {"key": "10", "DOI": "10.1016/S1470-2045(12)70379-0", "doi-asserted-by": "publisher"}, {"key": "11", "volume": "367", "issue": "13", "first-page": "1187", "year": "2012", "journal-title": "The New England Journal of Medicine", "DOI": "10.1056/NEJMoa1207506", "doi-asserted-by": "crossref"}, {"key": "12", "volume": "13", "issue": "12", "first-page": "1210", "year": "2012", "journal-title": "The Lancet Oncology", "DOI": "10.1016/S1470-2045(12)70473-4", "doi-asserted-by": "crossref"}, {"key": "13", "volume": "23", "year": "2012", "journal-title": "Annals of Oncology"}, {"key": "14", "volume": "23", "year": "2012", "journal-title": "Annals of Oncology"}, {"key": "15", "DOI": "10.1056/NEJMoa1014618", "doi-asserted-by": "publisher"}, {"key": "38", "DOI": "10.1016/S0140-6736(10)62344-6", "doi-asserted-by": "publisher"}, {"key": "43", "DOI": "10.1016/0277-5379(91)90257-E", "doi-asserted-by": "publisher"}, {"key": "47", "volume": "16", "issue": "4", "first-page": "1574", "year": "1998", "journal-title": "Journal of Clinical Oncology", "DOI": "10.1200/JCO.1998.16.4.1574", "doi-asserted-by": "crossref"}, {"key": "48", "DOI": "10.1016/j.urology.2004.01.034", "doi-asserted-by": "publisher"}, {"key": "56", "DOI": "10.1002/cncr.22431", "doi-asserted-by": "publisher"}, {"key": "60", "volume": "30", "issue": "18", "year": "2012", "journal-title": "Journal of Clinical Oncology"}, {"key": "16", "DOI": "10.1038/sj.pcan.4500607", "doi-asserted-by": "publisher"}, {"key": "17", "volume": "80", "issue": "8", "first-page": "1652", "year": "1997", "journal-title": "Cancer"}, {"key": "18", "DOI": "10.1200/JCO.2003.05.147", "doi-asserted-by": "publisher"}, {"key": "19", "DOI": "10.1200/JCO.2003.03.042", "doi-asserted-by": "publisher"}, {"key": "20", "volume": "95", "issue": "17", "first-page": "1300", "year": "2003", "journal-title": "Journal of the National Cancer Institute", "DOI": "10.1093/jnci/djg038", "doi-asserted-by": "crossref"}, {"key": "21", "DOI": "10.1016/S1470-2045(09)70201-3", "doi-asserted-by": "publisher"}, {"key": "22", "volume": "8", "issue": "23", "first-page": "2221", "year": "2009", "journal-title": "Cancer Biology and Therapy", "DOI": "10.4161/cbt.8.23.9983", "doi-asserted-by": "crossref"}, {"key": "23", "DOI": "10.1093/annonc/mdr435", "doi-asserted-by": "publisher"}, {"key": "24", "DOI": "10.1080/07357900802208608", "doi-asserted-by": "publisher"}, {"key": "25", "volume": "2", "issue": "1", "first-page": "7", "year": "2006", "journal-title": "Journal of Oncology Practice", "DOI": "10.1200/JOP.2.1.7", "doi-asserted-by": "crossref"}, {"key": "26", "DOI": "10.1634/theoncologist.9-90004-28", "doi-asserted-by": "publisher"}, {"key": "27", "volume": "7", "issue": "5", "first-page": "513", "year": "1992", "journal-title": "Journal of Bone and Mineral Research"}, {"key": "28", "DOI": "10.1006/bbrc.1998.8586", "doi-asserted-by": "publisher"}, {"key": "29", "DOI": "10.1073/pnas.95.7.3597", "doi-asserted-by": "publisher"}, {"key": "30", "DOI": "10.1083/jcb.145.3.527", "doi-asserted-by": "publisher"}, {"key": "31", "DOI": "10.1006/bbrc.2000.3129", "doi-asserted-by": "publisher"}, {"key": "32", "volume": "157", "issue": "2", "first-page": "435", "year": "2000", "journal-title": "American Journal of Pathology", "DOI": "10.1016/S0002-9440(10)64556-7", "doi-asserted-by": "crossref"}, {"key": "33", "DOI": "10.1016/j.molmed.2005.11.007", "doi-asserted-by": "publisher"}, {"key": "34", "DOI": "10.1158/1078-0432.CCR-05-1933", "doi-asserted-by": "publisher"}, {"key": "35", "DOI": "10.1200/JCO.2008.19.2146", "doi-asserted-by": "publisher"}, {"key": "36", "DOI": "10.1093/annonc/mdq037", "doi-asserted-by": "publisher"}, {"key": "37", "DOI": "10.1056/NEJMoa0809003", "doi-asserted-by": "publisher"}, {"key": "39", "DOI": "10.1016/S0140-6736(11)61226-9", "doi-asserted-by": "publisher"}, {"key": "40", "DOI": "10.1016/j.canlet.2012.04.001", "doi-asserted-by": "publisher"}, {"key": "41", "year": "2008"}, {"key": "42", "volume": "14", "issue": "7-8", "first-page": "349", "year": "1988", "journal-title": "European Journal of Nuclear Medicine"}, {"key": "44", "volume": "25", "issue": "5", "first-page": "805", "year": "1993", "journal-title": "International Journal of Radiation Oncology Biology Physics", "DOI": "10.1016/0360-3016(93)90309-J", "doi-asserted-by": "crossref"}, {"key": "45", "DOI": "10.1016/0167-8140(94)90411-1", "doi-asserted-by": "publisher"}, {"key": "46", "DOI": "10.1016/S0302-2838(03)00364-6", "doi-asserted-by": "publisher"}, {"key": "49", "issue": "4", "year": "2003", "journal-title": "Cochrane Database of Systematic Reviews"}, {"key": "51", "volume": "64", "issue": "765", "first-page": "817", "year": "1991", "journal-title": "British Journal of Radiology"}, {"key": "52", "DOI": "10.1016/S1470-2045(05)70206-0", "doi-asserted-by": "publisher"}, {"key": "50", "volume": "26", "issue": "4", "first-page": "345", "year": "1985", "journal-title": "Journal of Nuclear Medicine"}, {"key": "53", "DOI": "10.1007/s002590050143", "doi-asserted-by": "publisher"}, {"key": "54", "volume": "7", "issue": "12", "first-page": "1926", "year": "1989", "journal-title": "Journal of Clinical Oncology", "DOI": "10.1200/JCO.1989.7.12.1926", "doi-asserted-by": "crossref"}, {"key": "55", "DOI": "10.1016/S0959-8049(97)00155-X", "doi-asserted-by": "publisher"}, {"key": "57", "volume": "26", "issue": "4", "first-page": "330", "year": "2012", "journal-title": "Oncology"}, {"key": "58", "DOI": "10.1016/S1470-2045(07)70147-X", "doi-asserted-by": "publisher"}, {"key": "59", "DOI": "10.1158/1078-0432.CCR-04-2244", "doi-asserted-by": "publisher"}, {"key": "61", "DOI": "10.1200/JCO.2008.20.4164", "doi-asserted-by": "publisher"}, {"key": "62", "DOI": "10.1200/JCO.2008.20.5393", "doi-asserted-by": "publisher"}, {"key": "63", "volume": "31", "year": "2013", "journal-title": "Journal of Clinical Oncology"}, {"key": "64", "DOI": "10.1200/JCO.2008.18.9811", "doi-asserted-by": "publisher"}, {"key": "65", "DOI": "10.1016/S0140-6736(00)03639-4", "doi-asserted-by": "publisher"}, {"key": "66", "volume": "31", "year": "2013", "journal-title": "Journal of Clinical Oncology"}, {"key": "67", "volume": "31", "issue": "4", "first-page": "412", "year": "2013", "journal-title": "Journal of Clinical Oncology", "DOI": "10.1200/JCO.2012.45.0494", "doi-asserted-by": "crossref"}, {"key": "68", "DOI": "10.1158/1078-0432.CCR-13-0319", "doi-asserted-by": "publisher"}, {"key": "69", "DOI": "10.1016/j.ctrv.2009.11.005", "doi-asserted-by": "publisher"}, {"key": "70", "DOI": "10.1002/cncr.26204", "doi-asserted-by": "publisher"}, {"key": "71", "DOI": "10.1158/1078-0432.CCR-09-1691", "doi-asserted-by": "publisher"}, {"key": "72", "volume": "6", "year": "2013", "journal-title": "Journal of Clinical Oncology"}, {"key": "73", "volume": "31", "year": "2013", "journal-title": "Journal of Clinical Oncology"}, {"key": "75", "DOI": "10.1016/S0140-6736(10)61389-X", "doi-asserted-by": "publisher"}, {"key": "74", "volume": "368", "issue": "15", "first-page": "1458", "year": "2013", "journal-title": "The New England Journal of Medicine"}], "container-title": ["Prostate Cancer"], "language": "en", "link": [{"URL": "http://downloads.hindawi.com/journals/pc/2013/210686.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://downloads.hindawi.com/journals/pc/2013/210686.xml", "content-type": "application/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://downloads.hindawi.com/journals/pc/2013/210686.pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 6, 21]], "date-time": "2017-06-21T20:53:05Z", "timestamp": 1498078385000}, "score": 20.907011, "issued": {"date-parts": [[2013]]}, "references-count": 75, "alternative-id": ["210686", "210686"], "URL": "http://dx.doi.org/10.1155/2013/210686", "relation": {"cites": []}, "ISSN": ["2090-3111", "2090-312X"], "issn-type": [{"value": "2090-3111", "type": "print"}, {"value": "2090-312X", "type": "electronic"}], "subject": ["Urology", "Cancer Research", "Oncology"]}, {"institution": {"name": "University of Louisville", "place": ["-"], "acronym": ["-"]}, "indexed": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T11:03:59Z", "timestamp": 1574852639710}, "reference-count": 0, "publisher": "University of Louisville", "content-domain": {"domain": [], "crossmark-restriction": false}, "DOI": "10.18297/etd/2801", "type": "dissertation", "created": {"date-parts": [[2017, 10, 30]], "date-time": "2017-10-30T17:33:33Z", "timestamp": 1509384813000}, "approved": {"date-parts": [[2017]]}, "source": "Crossref", "is-referenced-by-count": 0, "title": ["Prevention and treatment of familial adenomatous polyposis and colorectal cancer by bilberry-derived anthocyanidins."], "prefix": "10.18297", "author": [{"given": "Ashley", "family": "Mudd", "sequence": "first", "affiliation": []}], "member": "7638", "deposited": {"date-parts": [[2017, 10, 30]], "date-time": "2017-10-30T17:33:49Z", "timestamp": 1509384829000}, "score": 20.801609, "issued": {"date-parts": [[null]]}, "references-count": 0, "URL": "http://dx.doi.org/10.18297/etd/2801"}, {"indexed": {"date-parts": [[2019, 11, 18]], "date-time": "2019-11-18T23:15:33Z", "timestamp": 1574118933690}, "reference-count": 0, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[1993, 1, 1]], "date-time": "1993-01-01T00:00:00Z", "timestamp": 725846400000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["European Journal of Cancer"], "published-print": {"date-parts": [[1993, 1]]}, "DOI": "10.1016/0959-8049(93)92051-s", "type": "journal-article", "created": {"date-parts": [[2004, 4, 18]], "date-time": "2004-04-18T00:40:00Z", "timestamp": 1082248800000}, "page": "S254", "source": "Crossref", "is-referenced-by-count": 2, "title": ["A survey of the opinions on \u2018informed consent\u2019 of women attending a breast unit"], "prefix": "10.1016", "volume": "29", "author": [{"given": "AM", "family": "Maslin", "sequence": "first", "affiliation": []}, {"given": "TJ", "family": "Powles", "sequence": "additional", "affiliation": []}, {"given": "M", "family": "Baum", "sequence": "additional", "affiliation": []}, {"given": "S", "family": "Ashley", "sequence": "additional", "affiliation": []}, {"given": "VA", "family": "Tidy", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["European Journal of Cancer"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:095980499392051S?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:095980499392051S?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 2, 13]], "date-time": "2019-02-13T06:21:21Z", "timestamp": 1550038881000}, "score": 20.735046, "issued": {"date-parts": [[1993, 1]]}, "references-count": 0, "alternative-id": ["095980499392051S"], "URL": "http://dx.doi.org/10.1016/0959-8049(93)92051-s", "ISSN": ["0959-8049"], "issn-type": [{"value": "0959-8049", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T20:59:22Z", "timestamp": 1574283562967}, "publisher-location": "100 Barr Harbor Drive, PO Box C700, West Conshohocken, PA 19428-2959", "reference-count": 0, "publisher": "ASTM International", "isbn-type": [{"value": "9780803120310", "type": "print"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "DOI": "10.1520/stp11718s", "type": "book-chapter", "created": {"date-parts": [[2009, 3, 4]], "date-time": "2009-03-04T21:29:00Z", "timestamp": 1236202140000}, "page": "323-323-21", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Behavioral Studies of Contaminant Effects on Aquatic Invertebrates: A Review of Russian Investigations"], "prefix": "10.1520", "author": [{"given": "VA", "family": "Nepomnyashchikh", "sequence": "first", "affiliation": []}, {"given": "VA", "family": "DeLonay", "sequence": "additional", "affiliation": []}, {"given": "EE", "family": "Little", "sequence": "additional", "affiliation": []}], "member": "381", "container-title": ["Environmental Toxicology and Risk Assessment: Biomarkers and Risk Assessment: Fifth Volume"], "deposited": {"date-parts": [[2015, 4, 7]], "date-time": "2015-04-07T18:15:44Z", "timestamp": 1428430544000}, "score": 20.606268, "issued": {"date-parts": [[null]]}, "ISBN": ["9780803120310"], "references-count": 0, "URL": "http://dx.doi.org/10.1520/stp11718s"}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T12:25:43Z", "timestamp": 1574771143398}, "reference-count": 0, "publisher": "Harborside Press, LLC", "issue": "5S", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["J Natl Compr Canc Netw"], "published-print": {"date-parts": [[2016, 5]]}, "DOI": "10.6004/jnccn.2016.0185", "type": "journal-article", "created": {"date-parts": [[2017, 4, 14]], "date-time": "2017-04-14T16:08:17Z", "timestamp": 1492186097000}, "page": "659-662", "source": "Crossref", "is-referenced-by-count": 2, "title": ["Multigene Testing in Localized Prostate Cancer"], "prefix": "10.6004", "volume": "14", "author": [{"given": "Ashley E.", "family": "Ross", "sequence": "first", "affiliation": []}], "member": "4047", "published-online": {"date-parts": [[2016, 5, 25]]}, "container-title": ["Journal of the National Comprehensive Cancer Network"], "language": "en", "deposited": {"date-parts": [[2019, 3, 4]], "date-time": "2019-03-04T17:13:28Z", "timestamp": 1551719608000}, "score": 20.283337, "issued": {"date-parts": [[2016, 5]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2016, 5, 25]]}, "published-print": {"date-parts": [[2016, 5]]}, "issue": "5S"}, "alternative-id": ["10.6004/jnccn.2016.0185"], "URL": "http://dx.doi.org/10.6004/jnccn.2016.0185", "ISSN": ["1540-1405", "1540-1413"], "issn-type": [{"value": "1540-1405", "type": "print"}, {"value": "1540-1413", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 12, 5]], "date-time": "2019-12-05T14:14:10Z", "timestamp": 1575555250259}, "reference-count": 0, "publisher": "AACN Publishing", "issue": "6", "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[1998, 11, 1]]}, "abstract": "<jats:p>Accurate recognition of signs and symptoms and prompt diagnosis of myocardial infarction are essential for preserving myocardial function and saving lives. However, measurements of cardiac enzymes such as creatine kinase, lactate dehydrogenase, and their isoenzymes do not always provide accurate clinical diagnosis, particularly in patients with other concomitant diseases. Recently, alternative biomarkers of cardiac disease have been described: creatine kinase mass, cardiac troponins, and myoglobin. All cardiac biomarkers have some clinical usefulness in diagnosing acute coronary syndrome and acute myocardial infarction. Indications for use vary for each biomarker, and each has advantages and disadvantages and can be used at various times. However, the following must be considered: (1) Serial testing is essential with any biomarker. (2) None of the current biomarkers can be used to detect myocardial ischemia. (3) The decision of which biomarker to use should be based on the capabilities of the healthcare facility and the signs and symptoms of the patient.</jats:p>", "DOI": "10.4037/ajcc1998.7.6.418", "type": "journal-article", "created": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T07:01:58Z", "timestamp": 1574751718000}, "page": "418-423", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Cardiac biomarkers: past, present, and future"], "prefix": "10.4037", "volume": "7", "author": [{"given": "Adams", "family": "JE3rd", "sequence": "first", "affiliation": []}, {"given": "VA", "family": "Miracle", "sequence": "additional", "affiliation": []}], "member": "2471", "container-title": ["American Journal of Critical Care"], "language": "en", "link": [{"URL": "https://aacnjournals.org/ajcconline/article/7/6/418/6333/Cardiac-biomarkers-past-present-and-future", "content-type": "application/pdf", "content-version": "vor", "intended-application": "syndication"}, {"URL": "https://aacnjournals.org/ajcconline/article/7/6/418/6333/Cardiac-biomarkers-past-present-and-future", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T09:24:01Z", "timestamp": 1574760241000}, "score": 20.0776, "issued": {"date-parts": [[1998, 11, 1]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[1998, 11, 1]]}, "issue": "6"}, "URL": "http://dx.doi.org/10.4037/ajcc1998.7.6.418", "ISSN": ["1062-3264", "1937-710X"], "issn-type": [{"value": "1062-3264", "type": "print"}, {"value": "1937-710X", "type": "electronic"}], "subject": ["Critical Care", "General Medicine"]}, {"indexed": {"date-parts": [[2019, 11, 18]], "date-time": "2019-11-18T16:57:27Z", "timestamp": 1574096247485}, "reference-count": 14, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[1995, 12, 1]], "date-time": "1995-12-01T00:00:00Z", "timestamp": 817776000000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Toxicology Letters"], "published-print": {"date-parts": [[1995, 12]]}, "DOI": "10.1016/0378-4274(95)03568-0", "type": "journal-article", "created": {"date-parts": [[2002, 7, 25]], "date-time": "2002-07-25T13:40:01Z", "timestamp": 1027604401000}, "page": "373-378", "source": "Crossref", "is-referenced-by-count": 15, "title": ["Case studies of the use of biomarkers to assess exposures"], "prefix": "10.1016", "volume": "82-83", "author": [{"given": "L.L.", "family": "Needham", "sequence": "first", "affiliation": []}, {"given": "D.L.", "family": "Ashley", "sequence": "additional", "affiliation": []}, {"suffix": "Jr.", "given": "D.G.", "family": "Patterson", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Toxicology Letters"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:0378427495035680?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:0378427495035680?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 4, 29]], "date-time": "2019-04-29T06:23:46Z", "timestamp": 1556519026000}, "score": 20.065079, "issued": {"date-parts": [[1995, 12]]}, "references-count": 14, "alternative-id": ["0378427495035680"], "URL": "http://dx.doi.org/10.1016/0378-4274(95)03568-0", "ISSN": ["0378-4274"], "issn-type": [{"value": "0378-4274", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 24]], "date-time": "2019-11-24T00:27:58Z", "timestamp": 1574555278368}, "reference-count": 136, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2015, 5, 1]], "date-time": "2015-05-01T00:00:00Z", "timestamp": 1430438400000}, "delay-in-days": 0, "content-version": "tdm"}], "funder": [{"name": "National Institutes of Health/National Institutes of Neurological Disorders and Stroke", "award": ["NS068179", "NS061867"]}], "content-domain": {"domain": ["elsevier.com", "sciencedirect.com"], "crossmark-restriction": true}, "short-container-title": ["Brain Research"], "published-print": {"date-parts": [[2015, 5]]}, "DOI": "10.1016/j.brainres.2014.10.031", "type": "journal-article", "created": {"date-parts": [[2014, 10, 24]], "date-time": "2014-10-24T22:15:11Z", "timestamp": 1414188911000}, "page": "94-107", "update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy", "source": "Crossref", "is-referenced-by-count": 22, "title": ["Use of biomarkers in ALS drug development and clinical trials"], "prefix": "10.1016", "volume": "1607", "author": [{"given": "Nadine", "family": "Bakkar", "sequence": "first", "affiliation": []}, {"given": "Ashley", "family": "Boehringer", "sequence": "additional", "affiliation": []}, {"given": "Robert", "family": "Bowser", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Brain Research"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0006899314014334?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0006899314014334?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 8, 16]], "date-time": "2019-08-16T16:30:50Z", "timestamp": 1565973050000}, "score": 20.065079, "issued": {"date-parts": [[2015, 5]]}, "references-count": 136, "alternative-id": ["S0006899314014334"], "URL": "http://dx.doi.org/10.1016/j.brainres.2014.10.031", "ISSN": ["0006-8993"], "issn-type": [{"value": "0006-8993", "type": "print"}], "assertion": [{"value": "Elsevier", "name": "publisher", "label": "This article is maintained by"}, {"value": "Use of biomarkers in ALS drug development and clinical trials", "name": "articletitle", "label": "Article Title"}, {"value": "Brain Research", "name": "journaltitle", "label": "Journal Title"}, {"value": "https://doi.org/10.1016/j.brainres.2014.10.031", "name": "articlelink", "label": "CrossRef DOI link to publisher maintained version"}, {"value": "article", "name": "content_type", "label": "Content Type"}, {"value": "Copyright \u00a9 2014 Elsevier B.V. All rights reserved.", "name": "copyright", "label": "Copyright"}]}], "items-per-page": 20, "query": {"start-index": 0, "search-terms": null}}}